Orgenesis (ORGS) 10-K 29 Feb 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Nov. 30, 2015	Feb. 26, 2016	May. 29, 2015
Document Type	10-K
Amendment Flag	false
Document Period End Date	Nov. 30, 2015
Trading Symbol	orgs
Entity Registrant Name	Orgenesis Inc.
Entity Central Index Key	1,460,602
Current Fiscal Year End Date	--11-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		108,932,129
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Entity Public Float			$ 16,961,572
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Nov. 30, 2015	Nov. 30, 2014
CURRENT ASSETS:
Cash and cash equivalents	$ 4,168	$ 1,314
Accounts receivable	1,173	0
Prepaid expenses and other receivables	1,118	105
Grants receivable	1,446	811
Inventory	301	0
Total current assets	8,206	2,230
NON CURRENT ASSETS:
Property and equipment, net	4,296	13
Restricted cash	5	0
Intangible assets, net	16,653	0
Goodwill	9,535	0
Other assets	53	6
Total non current assets	30,542	19
TOTAL ASSETS	38,748	2,249
CURRENT LIABILITIES:
Accounts payable	3,475	1,084
Accrued expenses	816	375
Employee and related payables	1,348	626
Related parties	42	42
Advance payments on account of grant	307	85
Short-term loans and current maturities of long term loans	2,829	14
Deferred income	1,216	0
Convertible loans	3,022	2,437
Convertible bonds	1,888	0
Price protection derivative	1,533	0
TOTAL CURRENT LIABILITIES	16,476	4,663
LONG-TERM LIABILITIES:
Loans payable	2,540	0
Warrants	1,382	560
Retirement benefits obligation	5	5
Deferred taxes	3,327	0
TOTAL LONG-TERM LIABILITIES	7,254	565
TOTAL LIABILITIES	23,730	5,228
COMMITMENTS	0	0
REDEEMABLE COMMON STOCK	21,458	0
CAPITAL DEFICIENCY:
Common stock of $0.0001 par value, 1,750,000,000 shares authorized, 55,835,950 and 55,970,565 shares issued and outstanding as of November 30, 2015 and November 30, 2014, respectively	6	6
Additional paid-in capital	14,229	13,152
Receipts on account of shares to be allotted	1,251	60
Accumulated other comprehensive loss	(1,286)	(18)
Accumulated deficit	(20,640)	(16,179)
TOTAL CAPITAL DEFICIENCY	(6,440)	(2,979)
TOTAL LIABILITIES NET OF CAPITAL DEFICIENCY	$ 38,748	$ 2,249

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS PARENTHETICALS - $ / shares	Nov. 30, 2015	Nov. 30, 2014
Common Stock, par or stated value	$ 0.0001	$ 0.0001
Common Stock, shares authorized	1,750,000,000	1,750,000,000
Common Stock, shares issued	55,835,950	55,970,565
Common Stock, shares outstanding	55,835,950	55,970,565

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2015	Nov. 30, 2014
REVENUES	$ 2,974	$ 0
COST OF REVENUES	3,880	0
GROSS LOSS	906	0
RESEARCH AND DEVELOPMENT EXPENSES, net	1,067	1,549
AMORTIZATION OF INTANGIBLE ASSETS	1,203	0
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	4,035	3,028
OPERATING LOSS	7,211	4,577
FINANCIAL EXPENSES (INCOME), net	(1,850)	927
LOSS BEFORE INCOME TAXES	5,361	5,504
INCOME TAX BENEFIT	(900)	0
NET LOSS	$ 4,461	$ 5,504
LOSS PER SHARE:
Basic	$ 0.08	$ 0.10
Diluted	$ 0.11	$ 0.11
WEIGHTED AVERAGE NUMBER OF SHARES USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE:
Basic	55,798,416	54,162,596
Diluted	56,920,912	54,721,969
OTHER COMPREHENSIVE LOSS -
Net loss	$ 4,461	$ 5,504
Translation adjustments	1,268	18
TOTAL COMPREHENSIVE LOSS	$ 5,729	$ 5,522

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY/EQUITY - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Receipts on Account of Share to be Allotted [Member]	Accumulated Other Comprehensive Loss[Member]	Accumulated Deficit [Member]	Total
Beginning Balance at Nov. 30, 2013	$ 5	$ 8,635			$ (10,675)	$ (2,035)
Beginning Balance (Shares) at Nov. 30, 2013	51,144,621
Stock-based compensation to employees and directors		1,200				1,200
Stock-based compensation to service providers		1,287				1,287
Stock-based compensation to service providers (Shares)	913,333
Issuances of shares and warrants		1,214	$ 60			1,274
Issuances of shares and warrants (Shares)	2,479,628
Conversions of convertible loans into shares and warrants	$ 1	630				631
Conversions of convertible loans into shares and warrants (Shares)	713,023
Proceeds from exercise of stock options		1				1
Proceeds from exercise of stock options (Share)	623,806
Exercise of warrants into shares and warrants		50				50
Exercise of warrants into shares and warrants (Shares)	96,154
Beneficial conversion feature of convertible loans		135				135
Comprehensive loss for the year				$ (18)	(5,504)	(5,522)
Ending Balance at Nov. 30, 2014	$ 6	13,152	60	(18)	(16,179)	(2,979)
Ending Balance (Shares) at Nov. 30, 2014	55,970,565
Stock-based compensation to employees and directors		713				713
Stock-based compensation to service providers		90				90
Warrants issued to credit providers		208				208
Issuance of shares		60	(60)
Issuances of shares and warrants (Shares)	115,385
Shares cancellation (Shares)	(250,000)
Proceeds from exercise of stock options						0
Receipts on account of shares to be issued		6	1,251			1,257
Comprehensive loss for the year				(1,268)	(4,461)	(5,729)
Ending Balance at Nov. 30, 2015	$ 6	$ 14,229	$ 1,251	$ (1,286)	$ (20,640)	$ (6,440)
Ending Balance (Shares) at Nov. 30, 2015	55,835,950

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2015	Nov. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,461)	$ (5,504)
Adjustments required to reconcile net loss to net cash used in operating activities:
Stock-based compensation	803	2,487
Depreciation and amortization expenses	1,991	5
Change in fair value of warrants and embedded derivatives	(1,375)	(180)
Change in fair value of convertible bonds	(1,221)	0
Interest expense accrued on loans and convertible loans	502	1,086
Changes in operating assets and liabilities:
Increase in accounts receivable	(731)	0
Increase in inventory	(87)	0
Increase in other assets	(22)	0
Increase in prepaid expenses and other accounts receivable	(1,083)	(74)
Increase in accounts payable	1,497	1,016
Increase (decrease) in accrued expenses	538	(11)
Increase in employee and related payables	353	472
Increase in deferred income	1,039	0
Increase (decrease) in advance payments and receivables on account of grant	451	(726)
Decrease in deferred taxes	(900)	0
Net cash used in operating activities	(2,706)	(1,429)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(982)	(5)
Restricted cash	(5)	0
Short term investments and deposits	(250)	10
Acquisition of MaSTherCell, net of cash acquired, see	305	0
Amounts funded in respect of retirement benefits obligation	0	(3)
Net cash provided by (used in) investing activities	(932)	2
CASH FLOWS FROM FINANCING ACTIVITIES:
Short-term line of credit	(14)	14
Proceeds from issuance of shares and warrants	4,203	922
Proceeds from exercise of stock options	0	1
Proceeds from issuance of loans payable	3,946	0
Proceeds from exercise of warrants into shares and warrants	0	50
Repayment of short and long-term debt	(2,419)	0
Proceeds from issuance of convertible loans	950	1,750
Net cash provided by financing activities	6,666	2,737
NET CHANGE IN CASH AND CASH EQUIVALENTS	3,028	1,310
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(174)	(47)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	1,314	51
CASH AND CASH EQUIVALENTS AT END OF YEAR	4,168	1,314
SUPPLEMENTAL NON-CASH FINANCING ACTIVITY
Conversion of loans (including accrued interest) to common stock and warrants	0	631
Common stock issued for rended services	0	37
Warrants to be issued to credit providers	208	0
SUPPLEMENTAL INFORMATION ON INTEREST PAID IN CASH	$ 125	$ 0

GENERAL AND BASIS OF PRESENTATI

GENERAL AND BASIS OF PRESENTATION	12 Months Ended
	Nov. 30, 2015
GENERAL AND BASIS OF PRESENTATION [Text Block]	NOTE 1 – DESCRIPTION OF BUSINESS a. General Orgenesis Inc. (“the Company”) was incorporated in the state of Nevada on June 5, 2008. The Company is developing a technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into “pancreatic beta cell-like” insulin producing cells for patients with Type 1 Diabetes. On October 11, 2011, the Company incorporated a wholly owned subsidiary in Israel, Orgenesis Ltd. (the “Israeli Subsidiary”), which is engaged in research and development. On February 2, 2012, the Israeli Subsidiary entered into an agreement with Tel Hashomer Medical Research (“THM”), Infrastructure and Services Ltd (the “Licensor”). The Israeli Subsidiary was granted a worldwide, royalty bearing, exclusive license to transdifferentiation of cells to insulin producing cells, including the population of insulin producing cells, methods of making this population, and methods of using this population of cells for cell therapy or diabetes treatment developed by Dr. Sarah Ferber of THM. On July 31, 2013, the Company incorporated a wholly owned subsidiary in Maryland, Orgenesis Maryland Inc. (the “U.S. Subsidiary”), which is engaged in research and development. On October 11, 2013, the Company incorporated a wholly owned subsidiary in Belgium, Orgenesis SPRL (the “Belgian Subsidiary”), which is engaged in development and manufacturing activities together with clinical development studies in Europe, and later on to be the Company’s center for activities in Europe. As discussed in Note 3, on March 2, 2015, the Company completed the acquisition of MaSTherCell SA and Cell Therapy Holding SA (collectively “MaSTherCell”). MaSTherCell is a Contract Development and Manufacturing Organization (CDMO) specializing in cell therapy development for advanced medicinal products. Cell therapy is the prevention or treatment of human disease by the administration of cells that have been selected, multiplied and pharmacologically treated or altered outside the body (ex vivo). MaSTherCell's CDMO activity is operated as a separate reporting segment (See Note 4). As used in this report and unless otherwise indicated, the term “Company” refers to Orgenesis Inc. and its wholly-owned subsidiaries (“Subsidiaries”). Unless otherwise specified, all dollar amounts are expressed in United States dollars. b. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has net losses for the period from inception (June 5, 2008) through November 30, 2015 of $20.6 million, as well as negative cash flows from operating activities. Presently, the Company does not have sufficient cash resources to meet its plans in the twelve months following November 30, 2015. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management is in the process of evaluating various financing alternatives for operations, as the Company will need to finance future research and development activities and general and administrative expenses through fund raising in the public or private equity markets. The consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to obtain additional financing as may be required and ultimately to attain profitability. If the Company raises additional funds through the issuance of equity, the percentage ownership of current shareholders could be reduced, and such securities might have rights, preferences or privileges senior to its common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, the Company may not be able to take advantage of prospective business endeavors or opportunities, which could significantly and materially restrict its future plans for developing its business and achieving commercial revenues. If the Company is unable to obtain the necessary capital, the Company may have to cease operations. On December 7, 2015, and December 21, 2015, the Company entered into definitive agreements with accredited investors relating to a private placement (See Note 18(a)).

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Nov. 30, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Text Block]	NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accounting policies adopted are generally consistent with those of the previous financial year. Due to the acquisition of MaSTherCell, new accounting policies had to be adopted. a. Use of Estimates in the Preparation of Financial Statements The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statement date and the reported expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to the valuation of stock based compensation, valuation of financial instruments measured at fair value and valuation of intangible assets. b. Business Combination The Company allocates the purchase price of an acquired business to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Acquired in-process backlog, customer relations, brand name and know how are recognized at fair value. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets. Direct transaction costs associated with the business combination are expensed as incurred. The allocation of the consideration transferred in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The Company includes the results of operations of the business that it has acquired in its consolidated results prospectively from the date of acquisition. c. Cash equivalents The Company considers all short term, highly liquid investments, which include short term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. d. Restricted Cash The company has restricted cash deposited as a guarantee for the use of the Company's credit card. The Company classifies these amounts as a non-current asset since the Company expects to continue the use of the credit card. e. Research and Development, net Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, stock-based compensation expenses, payroll taxes and other employees' benefits, lab expenses, consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred. Participation from government departments and from research foundations for development of approved projects is recognized as a reduction of expense as the related costs are incurred. f. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned Subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. g. Functional Currency The currency of the primary economic environment in which the operations of the Company and part of its Subsidiaries are conducted is in U.S. dollars (“$” or “dollar”). The functional currency of the Belgian Subsidiaries is the Euro (“€” or “Euro”). Most of the Company’s expenses are incurred in dollars and the source of the Company’s financing has been provided in dollars. Thus, the functional currency of the Company and its Subsidiaries is the dollar. Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for nonmonetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions – exchange rates at transaction dates or average rates and (2) for other items (derived from nonmonetary balance sheet items such as depreciation) – historical exchange rates. The resulting transaction gains or losses are recorded as financial income or expenses. The financial statements of the Belgian Subsidiaries are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated at yearly average exchange rates during the year. Differences resulting from translation of assets and liabilities are presented as other comprehensive income. h. Inventory Inventory is stated at the lower of cost or net realizable value with cost determined under the first-in-first-out (FIFO) cost method. The entire balance of inventory at November 30, 2015, consists of raw material. i. Property and Equipment Property and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the related assets. Annual rates of depreciation are presented in the table below: Weighted Average Useful Life (Years) Production facility 10 Laboratory equipment 5 Office equipment and computers 3 - 5 j. Intangible Assets Intangible assets and their useful lives are as follows: Weighted Average Amortization Recorded at Useful Life (Years) Comprehensive Loss Line Item Backlog 1.75 Cost of revenues Customer Relationships 7.75 Amortization of intangible assets Brand 9.75 Amortization of intangible assets Know-How 11.75 Amortization of intangible assets Intangible assets are recorded at acquisition cost less accumulated amortization and impairment. Definite lived intangible assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over which the cash flows from the asset are expected to be generated. k. Goodwill Goodwill represents the excess of the purchase price of acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least annually (at November 30), at the reporting unit level or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test is applied by performing a qualitative assessment before calculating the fair value of the reporting unit. If, on the basis of qualitative factors, it is considered not more likely than not that the fair value of the reporting unit is less than the carrying amount, further testing of goodwill for impairment would not be required. Otherwise, goodwill impairment is tested using a two-step approach. The first step involves comparing the fair value of the reporting unit to its carrying amount. If the fair value of the reporting unit is determined to be greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount is determined to be greater than the fair value, the second step must be completed to measure the amount of impairment, if any. The second step involves calculating the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit from the fair value of the reporting unit as determined in step one. The implied fair value of the goodwill in this step is compared to the carrying value of goodwill. If the implied fair value of the goodwill is less than the carrying value of the goodwill, an impairment loss equivalent to the difference is recorded. l. Impairment of Long-lived Assets The Company reviews its property and equipment, intangible assets subject to amortization and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset class may not be recoverable. Indicators of potential impairment include: an adverse change in legal factors or in the business climate that could affect the value of the asset; an adverse change in the extent or manner in which the asset is used or is expected to be used, or in its physical condition; and current or forecasted operating or cash flow losses that demonstrate continuing losses associated with the use of the asset. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted cash flows. There were no impairment charges in 2015. m. Revenue Recognition The Company recognizes revenue for services linked to cell process development and cell manufacturing services based on individual contracts in accordance with ASC 605, Revenue Recognition, The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform. Cell manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met. For service agreement contracts where the Company is delivering services by executing more than one act, revenue is recognised based on the proportional performance method. Under this method, the costs are recognised in the income statement as incurred and the revenue recognized will be a proportion of the total contract consistent with the costs proportion of total costs. Any amounts invoiced to clients as a result of contractual terms are recognized as deferred income to the extent it exceeds the performance completed. The Company also incurs revenue of some consumables which are incidental to the services provided as foreseen in the clinical services contracts. The Company bills customers for reimbursable expenses and immediately recognizes these billings in revenue, as the revenue is deemed earned. n. Financial Liabilities Measured at Fair Value 1) Fair Value Option Topic 815 provides entities with an option to report certain financial assets and liabilities at fair value with subsequent changes in fair value reported in earnings. The election can be applied on an instrument by instrument basis. The Company elected the fair value option to its convertible bonds. The liability is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net (See also Note 14). 2) Warrants and Price Protection Mechanism Derivative Classified as a Liability Warrants that entitle the holder to down-round protection (through ratchet and anti-dilution provisions) and price protection mechanism derivatives in respect of shares entitled to down-round protection are classified as liabilities on the balance sheet. The liability is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net (See Note 14). 3) Derivatives Embedded derivatives are separated from the host contract and carried at fair value when (1) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract and (2) a separate, standalone instrument with the same terms would qualify as a derivative instrument. The derivative is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net. As to embedded derivatives arising from the issuance of convertible debentures, see Note 14. o. Income Taxes 1) With respect to deferred taxes, income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. 2) The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained on examination. If this threshold is met, the second step is to measure the tax position as the largest amount that is greater than 50% likely of being realized upon ultimate settlement. 3) Taxes that would apply in the event of disposal of investment in Subsidiaries have not been taken into account in computing the deferred income taxes, as it is the Company’s intention to hold these investments and not realize them. p. Stock-based Compensation The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718, Compensation - Stock Compensation The Company follows ASC Topic 505-50, Equity-Based Payments to Non-Employees q. Redeemable Common Stock Common stock with embedded redemption features, such as an unwind option, whose settlement is not at the Company’s discretion, are considered redeemable common stock. Redeemable common stock is considered to be temporary equity and are therefore presented as a mezzanine section between liabilities and equity on the Company's consolidated balance sheets. Subsequent adjustment of the amount presented in temporary equity is required only if the Company's management estimates that it is probable that the instrument will become redeemable. r. Loss per Share of Common Stock Net loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of common shares outstanding during the period. Diluted net loss per share is based upon the weighted average number of common shares and of common shares equivalents outstanding when dilutive. Common share equivalents include: (i) outstanding stock options under the Company’s Global Share Incentive Plan (2012) and warrants which are included under the treasury share method when dilutive, and (ii) common shares to be issued under the assumed conversion of the Company’s outstanding convertible debentures, which are included under the if-converted method when dilutive. The computation of diluted net loss per share for the year ended November 30, 2015 includes common share equivalents due to warrants (See Note 11). s. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, restricted cash and certain receivables. The Company held these instruments with highly rated financial institutions and the Company has not experienced any credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments. There is no bad debt allowance provided to date. t. Beneficial Conversion Feature (“BCF”) When the Company issues convertible debt, if the stock price is greater than the effective conversion price (after allocation of the total proceeds) on the measurement date, the conversion feature is considered "beneficial" to the holder. If there is no contingency, this difference is treated as issued equity and reduces the carrying value of the host debt; the discount is accreted as deemed interest on the debt (See Note 7). u. Other Comprehensive Loss Other comprehensive loss represents adjustments of foreign currency translation. v. Newly Issued Accounting Pronouncements In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements— Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. Continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Prior to this, there was no guidance under U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this update provide that guidance. In doing so, the amendments reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term “substantial doubt”, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). For the period ended November 30, 2015, management evaluated the Company’s ability to continue as a going concern and concluded that substantial doubt has not been alleviated about the Company’s ability to continue as a going concern. While the Company continues to explore further significant sources of financing, management’s assessment was based on the uncertainty related to the availability amount and nature of such financing over the next twelve months. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09) "Revenue from Contracts with Customers." ASU 2014-09 will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2016 (early adoption is not permitted). The guidance permits the use of either a retrospective or cumulative effect transition method. On July 9, 2015, the FASB decided to delay the effective date of the new revenue standard by one year. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The Company is currently evaluating the impact of this standard. In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2015-11 (ASU 2015-11), Simplifying the Measurement of Inventory During November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognise leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

ACQUISITION OF MASTHERCELL

ACQUISITION OF MASTHERCELL	12 Months Ended
	Nov. 30, 2015
ACQUISITION OF MASTHERCELL [Text Block]	NOTE 3 – ACQUISITION OF MASTHERCELL Description of the Transaction The Company entered into a share exchange agreement (the "Share Exchange Agreement") dated November 3, 2014 and addendum dated March 2, 2015 with MaSTherCell SA, Cell Therapy Holding SA (collectively “MaSTherCell”). According to the Share Exchange Agreement, in exchange for all of the issued and outstanding shares of MaSTherCell, the Company issued to the shareholders of MaSTherCell an aggregate of 42,401,724 shares (the “Consideration Shares”) of common stock at a price of $0.58 per share for an aggregate price of $24,593 thousand (the “Consideration Share Pricing”). Out of the Consideration Shares, 8,173,483 shares will be allocated to the bondholders of MaSTherCell in case of conversion (See "MaSTherCell convertible bonds" below). MaSTherCell SA and Cell Therapy Holding SA are companies incorporated in Belgium. All MaSTherCell shares were purchased either through Cell Therapy Holding SA or directly through MaSTherCell. MaSTherCell is a technology-driven, customer-oriented CDMO specializing in cellular therapy development for advanced medicinal products. To perform its services, MaSTherCell has a production and laboratory facility (the “GMP Unit”) that received the good manufacturing practice (GMP) authorization for production of advanced therapy medicinal products (ATMP) by the Belgian drug agency (AFMPS). The MaSTherCell acquisition is accounted for as a business combination. The results of operations of MaSTherCell have been included in the Company’s consolidated statements of operations starting from March 2, 2015, the date on which the Company obtained effective control of MaSTherCell. The revenue and net loss from operations of MaSTherCell for the period from March 2, 2015, the acquisition date, to November 30, 2015 was approximately $3 million and $2.3 million, respectively. As part of the agreement the parties agreed on certain post closing conditions, mainly related to a post closing financing of $10 million and a valuation which meets a threshold of $45 million. In the event that the Company did not achieve those conditions within eight (8) months of the closing date, MaSTherCell had an option to unwind the transaction (the “Unwind Option”) by delivering to the Company all of the Consideration Shares plus any amount that the Company has advanced or invested in MaSTherCell. On November 12, 2015, the Company and MaSTherCell and each of the shareholders of MaSTherCell (the “MaSTherCell Shareholders”), entered into an amendment (“Amendment No. 2”) to the Share Exchange Agreement. Under Amendment No. 2, the conditions under which the MaSTherCell Shareholders under the original agreement could unwind the transaction was extended to November 30, 2015. Under Amendment No. 2, the Company agreed to remit to MaSTherCell, by way of an equity investment, the sum of EUR3.8 million by November 30, 2015 (the “Initial Investment”), to be followed by a subsequent equity investment by December 31, 2015 in MaSTherCell of EUR1.2 million. These equity investments were to be made out of the proceeds from equity or equity-linked investments and/or credit facilities that the Company was required to have in place on or before November 30, 2015 in the aggregate amount of at least $10 million (the “Post Closing Financing”). The extended right of the MaSTherCell Shareholders to unwind the transaction could have been exercised by them only if the Company had not achieved the Post Closing Financing and/or completed the Initial Investment by November 30, 2015. As of November 30, 2015, the Company did not meet the above mentioned conditions and therefore the shares are presented as redeemable common stock. On December 10, 2015, the Company entered into definitive agreements with accredited investors relating to a private placement (the “Private Placement”) of (i) 8,227,647 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (ii) three year warrants (the “Investor Warrants”) to purchase up to an additional 8,227,647 shares of the Company’s Common Stock at a per share exercise price of $0.52. The purchased securities were issued pursuant to subscription agreements (each the “Subscription Agreements”) between the Company and the purchasers for aggregate proceeds to the Company of $4,278 thousand. From the proceeds of the Private Placement, on December 10, 2015 the Company remitted to MaSTherCell the Initial Investment of € 3.8 million or $4,103 thousand (out of the original obligation for investment of € 5 million), in compliance with its obligations as required under the Share Exchange Agreement. As a result, the right of the former MaSTherCell shareholders to unwind the merger with the Company was terminated. In connection with the Initial Investment, the Company agreed to invest € 2.2 million in MaSTherCell equity in addition to the Initial Investment. The Company’s agreement represents an increase of € 1 million over the amount which the Company was previously obligated to invest in MaSTherCell under Amendment No. 2 as additional equity and replaces any funding obligation that the Company had under the Share Exchange Agreement, as amended. MaSTherCell Convertible Bonds On September 18, 2014, MaSTherCell entered into convertible bond agreements with certain of MaSTherCell’s existing and new investors raising € 1.6 million (the “Convertible Bonds”). The bonds bear interest at an annual rate of 3% and will mature on September 18, 2016. As part of the original terms, each bond can be converted into 0.36 class A common shares of MaSTherCell (the “Conversion Shares”). As part of the Share Exchange Agreement, the parties agreed that, in case of conversion of the Convertible Bonds upon Uplisting (listing of the Company’s shares on NASDAQ or any other national exchange in the United States of America which provides at least the same level of liquidity) within 14 months of the closing date, the bondholders will be entitled to convert into a total of 8,173,483 out of the Consideration Shares. In case the bondholders elect not to convert the convertible bonds, or in case they are not allowed to convert in the absence of Uplisting within 14 months from the closing date and the convertible bonds remain a liability of MaSTherCell, then the Consideration Shares will be reduced by the amount remaining outstanding to the bondholders. To that effect, the number of Consideration Shares to be released back to the Company, shall be determined by dividing the subscription amount of the outstanding convertible bonds plus interest owed thereunder (converted into USD according to the currency exchange rate applicable on the day of conversion) by the consideration and by applying the resulting quotient to actual total number of Consideration shares. The Company records the convertible bonds on its consolidated balance sheet at their fair value (See Note 13). Fair Value of Consideration Transferred On the acquisition date, the fair value of the total consideration transferred to acquire MaSTherCell was as follows (in thousands): Total purchase consideration: Redeemable common stock $ 24,592 Less convertible bonds 3,134 Total fair value of consideration transferred $ 21,458 The following table summarizes the allocation of purchase price to the fair values of the assets acquired and liabilities assumed as of the acquisition date (in thousands): Total liabilities assumed: Total assets acquired: Cash and cash equivalents $ 305 Property and equipment 4,236 Inventory 231 Other current assets 1,664 Other intangible assets 18,977 Goodwill 10,106 Total assets 35,519 Total liabilities assumed: Deferred income 947 Deferred taxes 4,440 Loan payables 6,998 Other liabilities 1,676 Total liabilities 14,061 Total consideration transferred $ 21,458 The allocation of the purchase price to the net assets acquired and liabilities assumed resulted in the recognition of other intangible assets which comprised of: Customer Relationships of $349 thousand, Know-How of $17,037 thousand, Backlog of $250 thousand and Brand Name of $1,341 thousand. These other intangible assets have a useful life between 1.75 and 11.75 years. The useful life of the other intangible assets for amortization purposes was determined considering the period of expected cash flows generated by the assets used to measure the fair value of the intangible assets adjusted as appropriate for the entity-specific factors, including legal, regulatory, contractual, competitive, economic or other factors that may limit the useful life of intangible assets. The fair value of the Know How was estimated using a relief of royalties approach. Under this method, the fair value of the Know How is equal to the royalty fee that the owner of the Know How could profit from if he was to license the Know How out. The fair value of the Backlog was estimated using the income approach. An income and expense forecast was built based upon Backlog revenue estimates and the cost to perform each contract. On this basis, a free cash flow for the asset was derived, under several assumptions. Customer Relationships and Brand Name were estimated using a discounted cash flow method with the application of the multi-period excess earnings method. Under this method, an intangible asset’s fair value is equal to the present value of the incremental after-tax cash flows attributable only to the subject intangible asset after deducting contributory asset charges. An income and expenses forecast was built based upon specific intangible asset revenue and expense estimates. Acquired goodwill is not amortized unless impaired. Goodwill isn't amortized for tax purposes. Pro forma Impact of Business Combination The unaudited pro forma financial results have been prepared using the acquisition method of accounting and are based on the historical financial information of the Company and MaSTherCell. The unaudited pro forma condensed financial results have been prepared for illustrative purposes only and do not purport to be indicative of the results of operations that actually would have resulted had the acquisition of MaSTherCell occurred at the beginning of the fiscal year, or of future results of the combined entities. The unaudited pro forma condensed financial information does not reflect any operating efficiencies and expected realization of cost savings or synergies associated with the acquisition. Unaudited supplemental pro forma combined results of operations: Year Ended November 30, 2015 2014 (in thousands) Revenue $ 3,886 $ 1,606 Net loss $ 5,558 $ 9,573 Net loss per common share: Basic $ 0.10 $ 0.18 Diluted $ 0.13 $ 0.21 Adjustments for the unaudited supplemental pro forma combined results of operations are as follows: Year Ended November 30, 2015 2014 (in thousands) Amortization of intangibles $ 471 $ 2,124 Deferred income 88 400 Deferred tax (183 ) (354 ) Transaction costs (258 ) 258 Interest on convertible bonds (21 ) (1,483 ) Total $ 97 $ 945 Acquisition-related Costs Acquisition-related expenses consist of transaction costs which represent external costs directly related to the acquisition of MaSTherCell and primarily include expenditures for professional fees such as legal, accounting and other directly related incremental costs incurred to close the acquisition by both the Company and MaSTherCell. Acquisition-related expenses for the year ended November 30, 2015 were $258 thousand. These expenses were recorded to selling and general administrative expense in the consolidated statements of comprehensive loss.

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Nov. 30, 2015
SEGMENT INFORMATION [Text Block]	NOTE 4 - SEGMENT INFORMATION The Chief Executive Officer ("CEO") is the Company’s chief operating decision-maker ("CODM"). At November 30, 2015, following the acquisition of MaSTherCell, management has determined that there are two operating segments, based on the Company's organizational structure, its business activities and information reviewed by the CODM for the purposes of allocating resources and assessing performance. CDMO The Contract Development and Manufacturing Organization (“CDMO”) activity is operated by MaSTherCell, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: (i) process and assay development services and (ii) GMP contract manufacturing services. The CDMO segment includes only the results of MaSTherCell. CTB The Cellular Therapy Business (“CTB”) activity is based on our technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into “pancreatic beta cell-like” insulin producing cells for patients with Type 1 Diabetes. This segment is comprised of all entities aside from MaSTherCell. The Company assesses the performance based on a measure of "Adjusted EBIT" (earnings before financial expenses and tax, and excluding share-based compensation expenses and non-recurring income or expenses). The measure of assets has not been disclosed for each segment. Prior to the acquisition of MaSTherCell, the Company operated as one reporting segment. For this reason, the Company does not disclose comparative data for the year ended November 30, 2014. Segment data for the year ended November 30, 2015 is as follows: Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 3,320 $ $ (346 ) $ 2,974 Cost of revenues (3,099 ) (3,099 ) Research and development expenses, net (1,279 ) 346 (933 ) Operating expenses (1,304 ) (1,799 ) (3,103 ) Depreciation and amortization expense (1,984 ) (5 ) (1,989 ) Adjusted EBIT $ (3,067 ) $ (3,083) (6,150 ) Share-based compensation (803 ) (803 ) Acquistion costs (258 ) (258 ) Financial income 1,850 1,850 Loss before income tax (5,361 ) Geographic, Product and Customer Information Substantially all of the Company's revenues and long lived assets are located in Belgium. Net revenues from single customers from the CDMO segment that exceed 10% of total net revenues are: Year Ended November 30, 2015 (in thousands) Customer A $ 1,921 Customer B $ 626

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Nov. 30, 2015
PROPERTY AND EQUIPMENT [Text Block]	NOTE 5 – PROPERTY AND EQUIPMENT The following table represents the components of property and equipment: November 30, 2015 2014 (in thousands) Cost: Production facility $ 3,638 $ - Office furniture and computers 120 16 Lab equipment 1,200 6 4,958 22 Less – accumulated depreciation (662 ) (9 ) Total $ 4,296 $ 13 Depreciation expense for the years ended November 30, 2015 and 2014 was $681 thousand and $4 thousand, respectively.

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL	12 Months Ended
	Nov. 30, 2015
INTANGIBLE ASSETS AND GOODWILL [Text Block]	NOTE 6 – INTANGIBLE ASSETS AND GOODWILL Changes in the carrying amount of the Company’s goodwill for the year ended November 30, 2015 is as follows: November 30, 2015 (in thousands) Goodwill as of December 1, 2014 $ - Goodwill as acquired 10,106 Translation differences (571 ) Goodwill as of November 30,2015 $ 9,535 Goodwill Impairment The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performed a quantitative two-step assessment for goodwill impairment for the CDMO unit. As part of the first step of the two-step impairment test, the Company compared the fair value of the reporting units to their carrying values and determined that the carrying amount of the units do not exceed their fair values. The Company estimated the fair value of the unit by using an income approach based on discounted cash flows. The assumptions used to estimate the fair value of the Company’s reporting units were based on expected future cash flows and an estimated terminal value using a terminal year growth rate based on the growth prospects for each reporting unit. The Company used an applicable discount rate which reflected the associated specific risks for the CDMO unit future cash flows. Key assumptions used to determine the estimated fair value include: (a) expected cash flow for the five-year period following the testing date (including market share, sales volumes and prices, costs to produce and estimated capital needs); (b) an estimated terminal value using a terminal year growth rate of 3% determined based on the growth prospects ; and (c) a discount rate of 17.2% . Based on the Company’s assessment as of November 30, 2015, the carrying amount of its reporting unit does not exceeds its fair value. A decrease in the terminal year growth rate of 1% or an increase of 1% to the discount rate would reduce the fair value of the reporting unit by approximately $2.9 million and $3.4 million, respectively. These changes would not result in an impairment. Other Intangible Assets Other intangible assets consisted of the following: November 30, 2015 (In thousands) Gross Carrying Amount: Know How $ 16,073 Backlog 237 Customer relationships 330 Brand name 1,266 17,906 Accumulated amortization 1,253 Net carrying amount of other intangible assets $ 16,653 Intangible asset amortization expenses were approximately $1.3 million for the year ended November 30, 2015. Estimated aggregate amortization expenses for each of the five succeeding years ending November 30 th 2016 2017 to 2020 (in thousands) Amortization expenses $ 1,744 $ 1,608

CONVERTIBLE LOAN AGREEMENTS

CONVERTIBLE LOAN AGREEMENTS	12 Months Ended
	Nov. 30, 2015
CONVERTIBLE LOAN AGREEMENTS [Text Block]	NOTE 7 – CONVERTIBLE LOAN AGREEMENTS a. Nine Investments Limited Nine Investments may convert all or part of the loan into shares of the Company's common stock at $0.40 per share. The conversion price and the number of shares of common stock deliverable upon the conversion of the loan shall be subject to adjustment in the event and in the manner following: (i) if and whenever the Company’s common shares at any time outstanding shall be subdivided into a greater or consolidated into a lesser number of common shares, or in case of any capital reorganization or of any reclassification of the capital of the Company or in case of the consolidation, merger or amalgamation of the Company with or into any other company or of the sale of the assets of the Company as or substantially as an entirety or of any other company, the conversion price shall be decreased or increased proportionately; and (ii) in the event the Company issues any shares of common stock or securities convertible into shares at a price less than the conversion price, the conversion price shall be reduced for any unpaid or unconverted loan amount to the new issuance price. In addition, a consideration for entering into the loan agreement, on June 5, 2014, the Company issued to Nine Investments 500,000 shares of its common stock. The Company allocated the proceeds from Nine Investments between the shares and the convertible loan based on the relative fair value. In addition, the conversion right is detachable from the loan and classified as a derivative due to down round protection (full ratchet and anti-dilution provisions). Therefore, the Company attributed, to the conversion right derivative, out of the proceeds allocated to the convertible loan based on its fair value. The allocation of conversion right and shares represents a discount to the loan that will be accreted until the maturity date of the loan. The table below presents the fair value of the instruments issued as of the Closing Date and the allocation of the proceeds: Total Fair Allocation of Value Proceeds (in thousands) Loan component $ 1,262 $ 746 Shares component 250 180 Embedded derivative component 574 574 Total $ 2,086 $ 1,500 The Company estimated the fair value of the embedded derivative by using the Black-Scholes formula for option pricing using the following parameters: Share price $0.50 ; Exercise price $0.40 ; Volatility 94%; Dividend yield 0; Risk-free interest 0.05% and 80% likelihood for conversion. The bonus shares component was recorded as additional paid-in-capital and the fair value of the embedded derivative component is classified as a financial liability because the conversion price and the number of shares of common stock deliverable upon the conversion of the loan shall be subject to adjustment and will be measured in subsequent periods at fair value with changes in fair value charged to financial expenses or income, net. On December 31, 2014, the Company executed an amendment to the convertible loan agreement with Nine Investments Limited to extend the due date of the loan from December 31, 2014 to January 31, 2015. As of the date of the approval of these financial statements, the Company has not finalized the terms and revised maturity date of this loan, although it believes it will be successful in extending the agreement upon mutually agreeable terms as soon as practicable. The Company continues to accrete interest until the terms are agreed upon. b. Other Non U.S. Investors – Convertible Loans without Anti-Dilution In September 2014, the Company entered into convertible loans agreements for $150 thousand. The loans bear an annual interest rate of 6% and mature in six months, unless converted earlier. The lenders shall have the right to convert all or any portion of the outstanding principal amount and all accrued but unpaid interest thereon into shares of common stock of the Company at a conversion price of $0.40 per share. Since the stock price is greater than the effective conversion price (after allocation of the total proceeds) on the measurement date, the conversion features is considered "beneficial" to the holders and equal to $135 thousand. The difference is treated as issued equity and reduces the carrying value of the host debt; the discount is accreted as deemed interest on the debt. As of the date of this report, the Company has not finalized the terms and revised maturity date for these loans, although it believes it will be successful in extending the agreement upon mutually agreeable terms as soon as practicable. The Company continues to accrete interest until the terms are agreed upon. c. Other U.S. Investors and Non-U.S. Investors – Convertible Loans with Anti-Dilution During the year ended November 30, 2015, the Company entered into five convertible loan agreements with new investors for a total amount of $950 thousand as follows (the “2015 Convertible Notes”): Grant Date Maturity Date November 30, 2015 (in thousands) Convertible loan a June 9, 2015 December 9, 2015 $50 Convertible loan b June 16, 2015 December 16, 2015 250 Convertible loan c June 24, 2015 December 31, 2015 350 Convertible loan d October 15, 2015 October 15, 2016 50 Convertible loan e October 27, 2015 April 27, 2016 250 $950 Interest is calculated at 6% annually and is payable, along with the principal on or before the maturity date. The lenders have the right to convert all or part of the 2015 Convertible Notes (principal and the accrued interest) into shares of the Company’s common stock at a price per share equal to 75% of the Market Price (as defined below) (the "Conversion Price"), provided that the Conversion Price will not be less than $0.40 (the “Floor Price”). Market Price is defined as the average closing trading price for the Company’s common shares on the Over The Counter Market ("OTCQB") for the five trading days prior to the lender’s notice of conversion being delivered to the Company. The principal under the 2015 Convertible Notes shall automatically convert into units that include one common share and one warrant exercisable into one additional common share, upon the Qualified Offering (as defined below) at the same terms as the Qualified Offering. A Qualified Offering is defined as an offering of securities of the Company with gross proceeds equal to or greater than $5 to 6 million and with a price per share of the common stock underlying such Qualified Offering equal to or greater than the Floor Price. In the event the Company issues any common shares or securities convertible into common shares at a price less than the Floor Price (the "New Issuance Price"), the Floor Price shall be reduced for any unpaid or unconverted principal amount to the New Issuance Price. The conversion right is detachable from each of the 2015 Convertible Notes and classified as a derivative due to down-round protection (full ratchet and anti-dilution provisions). Therefore, the Company allocated the conversion derivative from each of the 2015 Convertible Notes based on their respective fair value. The allocation of conversion right represents a discount to the principal amount and will be accreted until the maturity date of each of the 2015 Convertible Notes. The table below presents the fair value as of the grant date: Embedded Loan Derivative Component Component (in thousands) Convertible loan a $ 46 $ 4 Convertible loan b 232 18 Convertible loan c 323 27 Convertible loan d 47 3 Convertible loan e 237 13 $ 885 $ 65 On December 23, 2015, the holders of all the 2015 Convertible Notes and the Company agreed to convert the 2015 Convertible Notes and accrued interest into units of the Company’s common stock, each unit comprising one share of the Company’s common stock and one three-year warrant to purchase an additional share of the Company’s common stock at an exercise price of $0.52. Each holder of 2015 Convertible Notes will receive a number of units equal to that holder’s investment in the 2015 Convertible Notes plus the accrued interest divided by $0.52. Furthermore, in the event the Company issues any common shares or securities convertible into common shares in a private placement for cash at a price less than $0.52 (the “New Issuance Price”) before December 23, 2016, the Company will issue, for no additional consideration, additional common shares to subscribers, according to the mechanism defined in the agreements. This provision does not apply to issuance of shares under options, issuance of shares under existing rights to acquire shares, nor issuance of shares for non-cash consideration.

LOANS

LOANS	12 Months Ended
	Nov. 30, 2015
LOANS [Text Block]	NOTE 8 – LOANS a. Terms of Long-term Loans Interest Rate Loan Amount November 30, Year of November 30, (in thousands) Grant Date 2015 Maturity 2015 (in thousands) Long-term loan a (*) € 1,400 August 1, 2012 4.05% 2022 $ 1,086 Long-term loan b € 1,000 August 13, 2012 6% - 7.5% 2023 1,089 Long-term loan c € 250 August 6, 2012, 6% 2022 205 Long-term loan d € 250 February 10, 2014 5.5% 2024 247 Long-term loan e € 290 April 23, 2015 5.5% 2020 350 Long-term loan f € 800 February 21, 2014 Euribord + 2% 2016 529 $ 3,506 Current portion of loans payable 966 $ 2,540 (*) For the loan from ING Bank in Belgium (“ING”), ING requested a business pledge on the Company assets for a value of € 1.4 million. b. Terms of Short-term Loans and Current Portion of Long Term Loans Amount in the Interest Rate Currency of November 30, November 30, Loan 2015 2015 (in thousands) Current portion of loans payable a Euro 4.05% $ 139 Current portion of loans payable b Euro 6% - 7.5% 166 Current portion of loans payable c Euro 6% 54 Current portion of loans payable d Euro 5.5% 35 Current portion of loans payable e Euro 5.5% 43 Current portion of loans payable f Euro Euribord + 2% 529 $ 966 Short term-loans* Euro 7% 1,334 Short term-loan** Euro 6.3% 529 $ 2,829 * On various dates from September 14, 2015 through the year 2015, MaSTherCell received short term loans from management and shareholders for a total amount of € 1,247 thousand, which bear an annual interest rate of 7%. No maturity dates were defined. ** On October 30, 2015, MaSTherCell received from ING bank in Belgium a short term credit facility for a maximum amount of € 500 thousand. The credit facility bears an interest rate of libor plus a margin defined by the bank. The maturity date of the loan is December 15, 2015.

COMMITMENTS

COMMITMENTS	12 Months Ended
	Nov. 30, 2015
COMMITMENTS [Text Block]	NOTE 9 - COMMITMENTS a. Tel Hashomer Medical Research, Infrastructure and Services Ltd. On February 2, 2012, the Company’s Israeli Subsidiary entered into a licensing agreement with THM Research, Infrastructure and Services Ltd (the “Licensor”). According to the agreement, the Israeli Subsidiary was granted a worldwide, royalty bearing, exclusive license to transdifferentiation of cells to insulin producing cells, including the population of insulin producing cells, methods of making this population, and methods of using this population of cells for cell therapy or diabetes treatment developed by Dr. Sarah Ferber of THM.. As consideration for the license, the Israeli Subsidiary will pay the following to the Licensor: 1) A royalty of 3.5% of net sales; 2) 16% of all sublicensing fees received; 3) An annual license fee of $15 thousand, which commenced on January 1, 2012 and shall be paid once every year thereafter (the “Annual Fee”). The Annual Fee is non-refundable, but it shall be credited each year due, against the royalty noted above, to the extent that such are payable, during that year; and 4) Milestone payments as follows: a) $50 thousand on the date of initiation of phase I clinical trials in human subjects; b) $50 thousand on the date of initiation of phase II clinical trials in human subjects; c) $150 thousand on the date of initiation of phase III clinical trials in human subjects; d) $750 thousand on the date of initiation of issuance of an approval for marketing of the first product by the FDA; and e) $2 million when worldwide net sales of Products (as defined in the agreement) have reached the amount of $150 million for the first time, (the “Sales Milestone”). As of November 30, 2015, the Israeli Subsidiary has not reached any of these milestones. In the event of closing of an acquisition of all of the issued and outstanding share capital of the Israeli Subsidiary and/or consolidation of the Israeli Subsidiary or the Company into or with another corporation (“Exit”), the Licensor shall be entitled to choose whether to receive from the Israeli Subsidiary a one-time payment based, as applicable, on the value of either 5,563,809 shares of common stock of the Company at the time of the Exit or the value of 1,000 shares of common stock of the Israeli Subsidiary at the time of the Exit. In May, 2014, the Israeli Subsidiary entered into a research service agreement with the Licensor. According to the agreement, the Licensor will perform a study at the facilities and use the equipment and personnel of the Chaim Sheba Medical Center (the “Hospital”), for the consideration of approximately $92 thousand for a year. In May 2015, the Israeli Subsidiary renewed the research agreement for an additional year with annual consideration of approximately $110 thousand. b. Pall Life Science Belgium BVBA On May 6, 2013, the Company entered into a Process Development Agreement with Pall Life Science Belgium BVBA (formerly ATMI BVBA), a Belgian Company that is a wholly owned Subsidiary of Pall Corporation (“Pall”), a U.S. publicly-traded company. According to the agreement, Pall will provide services in cell research. The Company will use Pall’s unique technology while the Company will provide to Pall the required materials for purpose of the study. According to the agreement, the Company will pay per achieved phase, as defined in the agreement, with a total consideration of approximately (€607) $642 thousand for all services. As of November 30, 2015, the Company received services in total value of $460 thousand. c. Maryland Technology Development Corporation On June 30, 2014, the Company’s U.S. Subsidiary entered into a grant agreement with Maryland Technology Development Corporation (“TEDCO”). TEDCO was created by the Maryland State Legislature in 1998 to facilitate the transfer and commercialization of technology from Maryland’s research universities and federal labs into the marketplace and to assist in the creation and growth of technology based businesses in all regions of the State. TEDCO is an independent organization that strives to be Maryland’s lead source for entrepreneurial business assistance and seed funding for the development of startup companies in Maryland’s innovation economy. TEDCO administers the Maryland Stem Cell Research Fund to promote State funded stem cell research and cures through financial assistance to public and private entities within the State. Under the agreement, TEDCO has agreed to give the U.S Subsidiary an amount not to exceed approximately $406 thousand (the “Grant”). The Grant will be used solely to finance the costs to conduct the research project entitled “Autologous Insulin Producing (AIP) Cells for Diabetes” during a period of two years. On July 22, 2014, the U.S Subsidiary received an advance payment of $203 thousand on account of the grant. Through November 30, 2015, the Company spent the full amount of the grant. On September 21, 2015 the U.S Subsidiary received the second advance payment in amount of $203 thousand. Through November 30, 2015, the Company utilized $11 thousand. The amount of grant that was utilized through November 30, 2015, was recorded as a deduction of research and development expenses in the statement of comprehensive loss. d. Department De La Gestion Financiere Direction De L’analyse Financiere (“DGO6”) On November 17, 2014, the Company's Belgian Subsidiary, received the formal approval from the Walloon Region, Belgium (Service Public of Wallonia, DGO6) for a € 2.015 million ($2.4 million) support program for the research and development of a potential cure for Type 1 Diabetes. The financial support is composed of a € 1,085 thousand ( 70% of budgeted costs) grant for the industrial research part of the research program and a further recoverable advance of € 930 thousand ( 60% of budgeted costs) of the experimental development part of the research program. The grants will be paid to the Belgian Subsidiary over a period of approximately 3 years. The grants are subject to certain conditions with respect to the Belgian Subsidiary’s work in the Walloon Region. In addition, the DGO6 is also entitled to a royalty upon revenue being generated from any commercial application of the technology. On December 9 and 16, 2014, the Belgian Subsidiary received € 651 thousand and € 558 thousand under the grant, respectively. Up through November 30, 2015, an amount of $1.4 million (€ 1.1 million) was recorded as deduction of research and development expenses and an amount of $114 thousand was recorded as advance payments on account of grant. On March 20, 2012, MaSTherCell had been granted an investment grant from the DGO6 for an amount of € 1,421 thousand. This grant is related to the investment in the production facility with a coverage of 32% of the investment planned. A first payment of € 568 thousand has been received in August 2013. The remaining part is expected to be paid by the end of fiscal 2016. e. Israel-U.S Binational Industrial Research and Development Foundation (“BIRD”) On September 9, 2015, the Israeli Subsidiary entered into a pharma Cooperation and Project Funding Agreement (CPFA) with BIRD and Pall Corporation, a U.S. company. BIRD will give a conditional grant of $400 thousand each (according to terms defined in the agreement), for a joint research and development project for the use Autologous Insulin Producing (AIP) Cells for the Treatment of Diabetes (the “Project”). The Project started on March 1, 2015. Upon the conclusion of product development, the grant shall be repaid at the rate of 5% of gross sales. The grant will be used solely to finance the costs to conduct the research of the project during a period of 18 months starting on March 1, 2015. Up through November 30, 2015, an amount of $153 thousand was recorded as deduction of research and development expenses and receivable on account of grant. On September 21, 2015, the Israeli Subsidiary received $100 thousand under the grant. f. Lease Agreement MaSTherCell has an operational lease agreement for the rent of offices for a period of 12 years expiring on November 30, 2027. The costs per year are € 28 thousand ($30 thousand). In January 2015, the Israeli subsidiary signed an operational lease agreement for the rent of labs and office for three years, which will be used for the research and development activities in Israel. The costs per year are NIS 120 thousand ($31 thousand). g. Collaboration agreement On November 12, 2015, the Company, through its wholly owned Israeli subsidiary, entered into a Collaboration Agreement (the “Collaboration Agreement) with Biosequel LLC, a company incorporated under the laws of Russia (“Biosequel”) to collaborate, on a non-exclusive basis, in carrying out clinical trials and eventually marketing the Company’s products in Russia, Belarus and Kazakhstan. The collaboration is divided into two stages, with the first focused on obtaining the requisite regulatory approvals for conducting clinical trials, as well as performing all clinical and other testing required for market authorization in the defined territory. The second stage will focus on marketing the products and will be subject to successful market acceptance. Biosequel will fund the costs for the first stage, which is expected to last for five or more years, but may terminate earlier if the necessary regulatory approvals are not obtained by the second anniversary of the agreement. The Collaboration Agreement is also terminable under certain limited conditions relating to a party’s insolvency or bankruptcy related event or breach of a material term of the agreement and force majeure events. The Company shall be the sole and exclusive owner of any and all results of the pre-marketing approval R&D and clinical trials. As of November 30, 2015, none of the requisite regulatory approvals for conducting clinical trials had been obtained.

CAPITAL DEFICIENCY

CAPITAL DEFICIENCY	12 Months Ended
	Nov. 30, 2015
CAPITAL DEFICIENCY [Text Block]	NOTE 10 – CAPITAL DEFICIENCY a. Share Capital The Company’s common shares are traded on the OTC Market Group’s OTCQB under the symbol “ORGS”. b. Financings 1) During the year 2014, the Company issued 1,773,079 units at a purchase price of $0.52 per unit to private investors in a non-brokered private placement for total consideration of $922 thousand. Each unit consisted of one share of the Company’s common stock and one non-transferable common share purchase warrant, with each warrant entitling the holder to acquire one additional share of the Company’s common stock at an exercise price of $0.52 per share for a period of three years. The fair value of these warrants as of the date of issuance was $625 thousand using the Black-Scholes valuation model based on the following assumptions: dividend yield of 0% for all years; expected volatility of 101%- 117%; risk free interest of 0.68% - 0.95%, and an expected life of three years. 2) On June 30, 2014, the Company entered into a debt settlement agreement with one creditor, whereby it settled a debt in the amount of $24 thousand by the issuance of 46,175 share of its common stock at a price per share of $0.52. On July 14, 2014, the Company entered into a debt settlement agreement with another creditor, whereby it settled a debt in the amount of $13 thousand by the issuance of 25,759 shares of its common stock at a price per share of $0.52. 3) In July 2014, one of the investors exercised warrants to purchase 96,154 shares of the Company’s common stock at an exercise price of $0.52 for a total consideration of $50 thousand. As an inducement to the investor to exercise the warrants, the Company issued the investor twice the number of warrants exercised, which was 192,308 new warrants, with each warrant entitling the holder to acquire one additional share of the Company’s common stock at an exercise price of $0.52 per share for a period of three years. The fair value of these warrants as of the date of issuance was $60 thousand using the Black-Scholes valuation model based on the following assumptions: dividend yield of 0% for all years; expected volatility of 103%; risk free interest of 0.98%, and an expected life of three years. 4) On various dates from October 27, 2015 up through November 30, 2015, the Company entered into definitive agreements with accredited investors relating to a private placement (the “Private Placement”) of (i) 8,083,416 shares of the Company’s common stock and (ii) three year warrants to purchase up to an additional 8,083,416 shares of the Company’s Common Stock at a per share exercise price of $0.52. The purchased securities were issued pursuant to subscription agreements between the Company and the purchasers for aggregate proceeds to the Company of $4,203 thousand. Furthermore, in the event the Company issues any common shares or securities convertible into common shares in a private placement for cash at a price less than $0.52 (the “New Issuance Price”) before November 30, 2016, the Company will issue, for no additional consideration, additional common shares to subscribers in the $0.52 per share which total each subscriber’s subscription proceeds divided by the New Issuance Price, minus the number of shares already issued to such subscriber. This provision does not apply to issuance of shares under options, issuance of shares under existing rights to acquire shares, nor issuance of shares for non-cash consideration (See also Note 14). The Company allocated the proceeds from the private placement based on the fair value of the warrants and the price protection derivative components. The residual amount was allocated to the shares. The table below presents the fair value of the instruments issued as of the Closing Date and the allocation of the proceeds (for the fair value as of November 30, 2015, see Note 14): Total Fair Value (in thousands) Warrants component $ 1,390 Price protection derivative component 1,529 Shares component 1,284 Total $ 4,203 c. Credit Facilities On October 30, 2015, the Company entered into securities purchase agreements with two accredited investors pursuant to which these lenders (”Lenders”) furnished to the Company access to a $5 million credit line (collectively, the “Credit Facility Agreements”). Pursuant to the Credit Facility Agreements, upon request the Company is entitled to receive $500 thousand or such lesser amount as may then be available under the credit facility (the “Advance Amount”), pro-rata from the credit providers under the Credit Facility Agreements, in consideration of which, it will issue to such persons, promissory notes for the amount advanced (each a “Credit Note”). The Company may draw down on the credit facility as needed until the entire $5.0 million is exhausted. Unless extended by mutual arrangement, the credit facility terminates on the earlier to occur of (i) November 30, 2016 and (ii) such time as the Company shall have raised in excess of $10 million in an equity investment. In consideration of the funding commitment under the Credit Facility Agreements, the Company issued to these Lenders 2,358,000 warrants to purchase up to an aggregate of shares of the Company’s Common Stock at a per share exercise price of $0.53 per share (the “Commitment Warrants”). The Commitment Warrants become first exercisable upon the scheduled expiration or termination of the credit facility through the third anniversary thereof. Additionally, upon the issuance of Credit Notes, the Lender is entitled to three year warrants (“Drawdown Warrants”) to purchase additional shares of the Company’s Common Stock in an amount equal to the quotient of: 0.50 X Advance Amount / $0.53. If the entire $5 million were drawn down by the Company, it would issue to the Lenders a total of 4,716,980 Drawdown Warrants. The fair value of the Commitment Warrants as of the date of issuance was $0.09 using the Black-Scholes valuation model based on the following assumptions: dividend yield of 0% for all years; expected volatility of 80%; risk free interest of 0.34% and an expected life of one year. All Credit Notes that may be issued under the Credit Facility Agreements mature on November 30, 2016. Interest on the outstanding principal amount of the Credit Notes accrues at a per annum rate of 12%, payable at maturity or upon an event of default. The Credit Notes contain customary events of default for transactions of this nature. Upon an event of default, the Lender has the right to require the Company to prepay the outstanding principal amount of the Credit Notes plus all accrued and unpaid interest. In addition, the Lender may require prepayment of the Credit Notes at par in connection with certain major transactions and the occurrence of certain other triggering events. d. Warrants As part of the Company’s private placements as described in Notes 10b, the Company issued warrants as follows: (1) Warrants which are subject to exercise price adjustments - presented as a financial liabilty as of November 30, 2015 Exercise Price / Number of Adjusted Number of Issuance Warrants Exercise Expiration Warrants Date Issued Price Date Outstanding October 27, 2015 192,308 $0.40 March 27, 2018 192,308 November 30, 2015 7,891,108 $0.40 November 30, 2018 7,891,108 8,083,416 8,083,416 For the fair value calculation of these warrants, see Note 14. (2) Warrants which are not subject to exercise price adjustments – presented in equity as of November 30, 2015 Exercise Price / Number of Adjusted Number of Grant Warrants Exercise Expiration Warrants Date Issued Price Date Outstanding March 2014 713,023 $0.52 March 2017 713,023 April 2014 384,615 $0.52 April 2017 384,615 July 2014 192,308 $0.52 July 2017 192,308 July 2014 144,230 $0.52 July 2017 144,230 August 2014 115,385 $0.52 August 2017 115,385 October 2015 2,358,490 $0.53 October 2018 2,358,490 3,908,051 3,908,051

LOSS PER SHARE

LOSS PER SHARE	12 Months Ended
	Nov. 30, 2015
LOSS PER SHARE [Text Block]	NOTE 11 – LOSS PER SHARE The following table sets forth the calculation of basic and diluted loss per share for the periods indicated: Year Ended November 30, 2015 2014 (in thousands, except per share data) Basic: Loss for the year $ 4,461 $ 5,504 Weighted average number of common shares outstanding 55,798,416 54,162,596 Loss per common share $ 0.08 $ 0.10 Diluted Loss for the year $ 4,461 5,504 Changes in fair value of embedded derivative and interest expenses on convertible bonds 1,272 Change in fair value of warrants 559 598 Loss for the year $ 6,292 6,102 Weighted average number of shares used in the computation of basic loss per share 55,798,416 54,162,596 Number of dilutive shares related to convertible bonds 873,380 Number of dilutive shares related to warrants 249,116 559,373 Weighted average number of common shares outstanding 56,920,912 54,721,969 Loss per common share $ 0.11 $ 0.11 Basic loss per share does not include 42,401,724 of redeemable common stock since the contingent criteria regarding the Unwind Option had not been met as of November 30, 2015. Diluted loss per share does not include 42,401,724 redeemable common stock, 12,899,314 shares underlying outstanding options, 7,546,750 shares issuable upon exercise of warrants and 1,100,000 shares upon conversion of convertible notes for the year ended November 30, 2015, because the effect of their inclusion in the computation would be anti-dilutive. Diluted loss per share does not include 15,267,559 shares underlying outstanding options, 400,000 shares due to stock-based compensation to service providers, 2,682,256 shares issuable upon exercise of warrants and 701,796 shares upon conversion of loans for the year ended November 30, 2014, because the effect of their inclusion in the computation would be anti-dilutive.

STOCK BASED COMPENSATION

STOCK BASED COMPENSATION	12 Months Ended
	Nov. 30, 2015
STOCK BASED COMPENSATION [Text Block]	NOTE 12 – STOCK-BASED COMPENSATION a. Global Share Incentive Plan On May 23, 2012, the Company's board of directors adopted the global share incentive plan (2012) ("Global Share Incentive Plan (2012) "). Under the Global Share Incentive Plan (2012), 12,000,000 shares of common stock have been reserved for the grant of options, which may be issued at the discretion of the Company's board of directors from time to time. Under this plan, each option is exercisable into one share of common stock of the Company. The options may be exercised after vesting and in accordance with the vesting schedule that will be determined by the Company's board of directors for each grant. The maximum contractual life term of the options is 10 years. b. Options Granted to Employees and Directors 1) On August 22, 2014, the Company approved an aggregate of 2,762,250 stock options to the Company’s Chief Executive Officer that are exercisable at $0.0001 per share. Out of the total approved, 414,304 options vested immediately with a fair value as of the date of grant of $261 thousand using the Black-Scholes valuation model, 1,242,996 options will vest quarterly over 4 years, with a fair value as of the date of grant of $783 thousand using the Black-Scholes valuation model, and 1,104,950 options will be vested pursuant to performance milestones that will be determined by the Compensation Committee of the Company's Board. Up to the date of this report, no performance milestones have been determined. All the options will expire on August 22, 2024. 2) On June 18, 2015, the Company approved an aggregate of 500,000 stock options to two directors that are exercisable at the market price on date of grant, or $0.53 per share. The options vest immediately and expire on June 18, 2020. The fair value of those options as of the date of grant was $136 thousand using the Black-Scholes valuation model. The volatility of stock-based compensation is based on historical volatility of the Company for the last two years. The expected term is the mid-point between the vesting date and the maximum contractual term for each grant equal to the contractual life. The fair value of each option grant is based on the following assumptions: Year Ended November 30, 2015 2014 Value of one common share $0.53 $0.53 - 0.63 Dividend yield 0% 0% Expected stock price volatility 85.7% 100.5 - 100.6% Risk free interest rate 1.68% 1.67 - 2.52% Expected term (years) 2.5 5 - 10 A summary of the Company's stock options granted to employees and directors as of November 30, 2015 and 2014 and changes for the years then ended is presented below: 2015 2014 Weighted Weighted Average Average Exercise Exercise Number of Price Number of Price Options $ Options $ Options outstanding at the beginning of the year 12,809,455 0.27 12,294,765 0.265 Changes during the year: Granted 500,000 0.53 2,707,300 0.194 Exercised (623,806 ) 0.001 Expired (2,440,120 ) 0.68 Forfeited (528,125 ) 0.5 (1,568,804 ) 0.205 Options outstanding at end of the year 10,341,210 0.16 12,809,455 0.27 Options exercisable at end of the year 8,696,162 0.09 9,661,548 0.568 Costs incurred with respect to stock-based compensation for employees and directors for the years ended November 30, 2015 and 2014 were $713 thousand and $1,200 thousand, respectively. As of November 30, 2015, there was $984 thousand of unrecognized compensation costs related to non-vested employees and directors stock options, to be recorded over the next 2.73 years. The following table presents summary information concerning the options granted to employees and directors outstanding as of November 30, 2015: Weighted Weighted Average Average Aggregate Exercise Number of Remaining Exercise Intrinsic Prices Outstanding Contractual Price Value $ Options Life $ $ (in thousands) 0.0001 4,439,205 7.1 0.0001 1,464 0.001 3,338,285 6.2 0.001 1,098 0.50 400,000 8.7 0.5 0.53 500,000 9.5 0.53 0.75 250,000 7.6 0.75 0.79 942,520 6.6 0.79 0.85 471,200 6.5 0.85 0.17 10,341,210 6.9 1.016 2,562 The following table presents summary of information concerning the options exercisable as of November 30, 2015: Exercise Number of Prices Exercisable $ Options Total (in thousands) 0.0001 3,584,645 0.3 0.001 3,338,285 3 0.50 325,000 163 0.53 500,000 265 0.75 100,000 75 0.79 565,512 447 0.85 282,720 240 8,696,162 1,193 c. Options Granted to Consultants and Service Providers 1) On April 3, 2014, the Company entered into a consulting agreement with Aspen Agency Limited, a Hong Kong corporation (“Aspen”), pursuant to which Aspen has agreed to provide investment banking, investor relations and business development services to the Company. In consideration for Aspen’s services, the Company agreed to issue to Aspen 3,000,000 stock options in two separate tranches of 1,000,000 and 2,000,000, with the second tranche vesting if they exercise the first tranche, to acquire shares of the Company’s common stock at an exercise price of $0.52 per share, for a period of three years. The fair value of the options was $744 thousand and was recorded as additional paid in capital in the balance sheet with a corresponding expense in general and administrative expenses. On October 23, 2014, the Company entered into a termination agreement with Aspen in which both parties agreed to terminate the consulting agreement and to cancel the first tranche of options. By way of cancellation of the first tranche of options, the second tranche was cancelled as well. The fair value of each option grant is estimated on the date of grant using a hybrid model combining a Monte Carlo simulation and Black-Scholes option pricing model with the following assumptions: Year Ended November 30, 2014 Value of one common share $0.51 Dividend yield 0% Expected stock price volatility 100% Risk free interest rate 0.11 - 0.95% Expected term (years) 1 - 3 2) On August 1, 2014, the Company granted an aggregate of 1,080,000 stock options to a consultant that are exercisable at $0.50, with 216,000 vesting immediately and 216,000 for each of the next four years. The options expire on August 1, 2018. The fair value of these options as of the date of grant was $403 thousand using the Black-Scholes option valuation model. The fair value of each stock option grant is estimated at the date of grant using the Black-Scholes valuation model. The volatility is based on historical volatilities of companies in comparable stages as well as the historical volatility of companies in the industry and, by statistical analysis of the daily share-pricing model. The volatility of stock-based compensation granted after November 30, 2013 is based on historical volatility of the Company for the last two years. The expected term is equal to the contractual life, based on management estimation for the expected dates of exercising of the options. The fair value of each option grant is based on the following assumptions: Year Ended November 30, 2015 2014 Value of one common share $0.65, 0.53 $0.53 Dividend yield 0% 0% Expected stock price volatility 86%, 89% 101% Risk free interest rate 1.34%, 1.42% 1.31% Expected term (years) 5 4 A summary of the status of the stock options granted to consultants and service providers as of November 30, 2015, and 2014 and changes for the years then ended is presented below: 2015 2014 Weighted Weighted Average Average Exercise Exercise Number of Price Number of Price Options $ Options $ Options outstanding at the beginning of the year 2,458,104 0.75 1,378,104 0.95 Changes during the year: Granted 200,000 0.51 2,080,000 0.51 Expired (1,000,000 ) 0.52 Options outstanding at end of the year 2,658,104 0.75 2,458,104 0.75 Options exercisable at end of the year 1,521,624 0.65 1,171,384 0.77 The following table presents summary information concerning the options granted to consultants and service providers outstanding as of November 30, 2015 (in thousands, except per share data): Weighted Weighted Average Average Aggregate Exercise Number of Remaining Exercise Instrinsic Prices Outstanding Contractual Price Value* $ Options Life $ $ 0.50 1,080,000 2.67 0.50 0.52 100,000 4.55 0.52 0.61 100,000 6.98 0.61 0.65 100,000 4.2 0.65 0.69 706,904 6.17 0.69 0.96 100,000 7.35 0.96 1.40 471,200 6.38 1.40 2,658,104 4.72 0.75 - * There is no instrinsic value, as all options are “out of the money” The following table presents summary of information concerning the options exercisable as of November 30, 2015 (in thousands, except per share data): Exercise Number of Total Prices Exercisable Exercise $ Options Value $ 0.50 432,000 216 0.61 60,000 37 0.69 706,904 488 0.96 40,000 38 1.40 282,720 396 1,521,624 1,175 Costs incurred with respect to stock-based compensation for consultants and service providers for the year ended November 30, 2015 and 2014 was $90 and $923, respectively. As of November 30, 2015, there was $260 thousand of unrecognized compensation costs related to non-vested consultants and service providers, to be recorded over the next 4.55 years.

TAXES

TAXES	12 Months Ended
	Nov. 30, 2015
TAXES [Text Block]	NOTE 13 – TAXES a. The Company and the US Subsidiary The Company and the US Subsidiary are taxed according to tax laws of the United States. The income of the Company is taxed in the United States at a rate of up to 35%. b. The Israeli Subsidiary The Israeli Subsidiary is taxed according to Israeli tax laws. The regular corporate tax rate in Israel for 2014 and 2015 is 26.5% . As of 2016, the tax rate has decreased to 25%. c. The Belgian Subsidiaries The Belgian Subsidiaries are taxed according to Belgian tax laws. The regular corporate tax rate in Belgium for 2014 and 2015 is 34%. d. Tax Loss Carryforwards 1) As of November 30, 2015, the Company had net operating loss (NOL) carry forwards equal to $4.3 million that is available to reduce future taxable income. The Company’s NOL carry forward is equal to $138 thousand, and may be restricted under Section 382 of the Internal Revenue Code (“IRC”). IRC Section 382 applies whenever a corporation with an NOL experiences an ownership change. As a result of Section 38 2, the taxable income for any post change year that may be offset by a pre-change NOL may not exceed the general Section 382 limitation, which is the fair market value of the pre-change entity multiplied by the long term tax exempt rate. 2) U.S. Subsidiary - As of November 30, 2015, the U.S. Subsidiary had approximately $494 thousand of NOL carry forwards that are available to reduce future taxable income with no limited period of use. 3) Israeli Subsidiary - As of November 30, 2015, the Israeli Subsidiary had approximately $3.2 million of NOL carry forwards that are available to reduce future taxable income with no limited period of use. 4) Belgian Subsidiaries - As of November 30, 2015, the Belgian Subsidiaries had approximately $8.3 million (€ 7.8 million) of NOL carry forwards that are available to reduce future taxable income with no limited period of use. e. Deferred Taxes The following table presents summary of information concerning the Company’s deferred taxes as of the periods ending November 30, 2015 and 2014 (in thousands): November 30, 2015 2014 (U.S dollars in thousands) Net operating loss carry forwards $ 5,658 $ 1,626 Research and development expenses (178 ) 230 Employee benefits 31 14 Property and equipment 268 Convertible bonds 45 Deferred income (508 ) Intangible assets (5,661 ) Less: Valuation allowance (2,982 ) (1,870 ) Net deferred tax liabilities $ (3,327 ) $ - Realization of deferred tax assets is contingent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards losses are expected to be available to reduce taxable income. As the achievement of required future taxable income is not considered more likely than not achievable, the Company and all of its subsidiaries except MaSTherCell have recorded full valuation allowance. The changes in valuation allowance are comprised as follows: Year Ended November 30, 2015 2014 (U.S dollars in thousands) Balance at the beginning of year $ (1,870 ) $ (1,212 ) Additions during the year (1,112 ) (658 ) Balance at end of year $ (2,982 ) $ (1,870 ) f. Reconciliation of the Theoretical Tax Expense to Actual Tax Expense The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for full valuation allowance with respect to tax benefits from carry forward tax losses. g. Tax Assessments 1) The Company - As of November 30, 2015, the Company has received a final tax assessment up to the year 2009. 2) U.S. Subsidiary and the Israeli Subsidiary - As of November 30, 2015, the U.S. Subsidiary and the Israeli Subsidiary have not received any final tax assessment. 3) Belgian Subsidiary - As of November 30, 2015, the Belgian Subsidiary has received a final tax assessment for the year 2014. 4) MaSTherCell - As of November 30, 2015, MaSTherCell has received a final tax assessment for the years 2012 to 2014. h. Uncertain Tax Provisions As of November 30, 2015, the Company has not accrued a provision for uncertain tax positions.

FAIR VALUE PRESENTATION

FAIR VALUE PRESENTATION	12 Months Ended
	Nov. 30, 2015
FAIR VALUE PRESENTATION [Text Block]	NOTE 14 - FAIR VALUE PRESENTATION The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: • Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. • Level 2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. • Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs, to the extent possible, and considers credit risk in its assessment of fair value. As of November 30, 2015 and 2014, the Company’s liabilities that are measured at fair value and classified as level 3 fair value are as follows (in thousands): November 30, November 30, 2015 2014 Level 3 Level 3 Warrants (1) $ 1,382 $ 560 Price protection derivative (1) 1,533 Embedded derivatives*(1) 289 992 Convertible bonds (2) $ 1,888 $ * The embedded derivative is presented in the Company's balance sheets on a combined basis with the related host contract (the convertible loans). ( 1) The fair value of the warrants, price protection derivatives and embedded derivatives is determined by using a Monte Carlo Simulation Model. This model, in contrast to the closed form model, such as the Black-Scholes Model, enables the Company to take into consideration the conversion price changes over the conversion period of the loan, and therefore is more appropriate in this case. ( 2) The fair value of the convertible bonds described in Note 7 is determined by using a binomial model for the valuation of the embedded derivative and the fair value of the bond was calculated based on the effective rate on the valuation date ( 6%). The binomial model used the forecast of the Company share price during the convertible bond's contractual term. Since the convertible bond is in Euro and the model is in USD, the Company has used the Euro/USD forward rates for each period. In order to solve for the embedded derivative fair value, the calculation was performed as follows: • Stage A - The model calculates a number of potential future share prices of the Company based on the volatility and risk-free interest rate assumptions. • Stage B - the embedded derivative value is calculated "backwards" in a way that takes into account the maximum value between holding the bonds until maturity or converting the bonds. The following table presents the assumptions that were used for the models as of November 30, 2015: Price Protection Derivative and Embedded Convertible Warrants Derivative Bonds Fair value of shares of common stock $ 0.33 $ 0.33 $ 0.33 Expected volatility 87%- 98% 87% 88% Discount on lack of marketability 14% - 18% Risk free interest rate 0.44%- 1.24% 0.11%-0.49% 0.42% Expected term (years) 2.9 - 3 0.08 - 0.87 0.8 Expected dividend yield 0% 0% 0% Expected capital raise dates Q2 2016-Q4 2016, Q4 2017 The following table presents the assumptions that were used for the models as of November 30, 2014: Embedded Warrants Derivative Value of one common share $0.65 $0.65 Dividend yield 0% 0% Expected stock price volatility 100% 100% Risk free interest rate 0.03 – 0.11% 0.04% Expected term (years) 0.3 – 0.8 0.08 Expected capital raise dates March 2015 March 2015 The table below sets forth a summary of the changes in the fair value of the Company’s financial liabilities classified as Level 3 for the year ended November 30, 2015 : Price Embedded Convertible Protection Warrants Derivatives Bonds Derivative (in thousands) Balance at beginning of the year $ 560 $ 992 $ - $ - Additions 1,390 112 3,234 1,526 Changes in fair value related to warrants expired* (525 ) - 7 Changes in fair value during the period (43 ) (815 ) (1,221 ) Translation adjustments - - (125 ) Balance at end of the year $ 1,382 $ 289 $ 1,888 $ 1,533 (*) During the twelve months ended November 30, 2015, 1,826,718 warrants have expired. There were no transfers to Level 3 during the twelve months ended November 30, 2015. The Company has performed a sensitivity analysis of the results for the warrants fair value to changes in the assumptions for expected volatility with the following parameters: Base -10% Base Base+10% (in thousands) As of November 30, 2015 $ 1,263 $ 1,382 $ 1,486 The Company has performed a sensitivity analysis of the results for the price protection derivative fair value to changes in the assumptions expected volatility with the following parameters: Base -10% Base Base+10% (in thousands) As of November 30, 2015 $ 1,502 $ 1,533 $ 1,552 The Company has performed a sensitivity analysis of the results for the convertible bonds fair value to changes in the assumptions expected volatility with the following parameters: Base -5% Base Base+5% (in thousands) As of November 30, 2015 $ 1,885 $ 1,888 $ 1,920 The table below sets forth a summary of the changes in the fair value of the Company’s financial liabilities classified as Level 3 for the year ended November 30, 2014 : Embedded Warrants Derivatives (in thousands) Balance at beginning of the year Additions $ 1,158 $ 574 Changes in fair value during the year (348 ) 418 Changes in fair value related to warrants expired (250 ) Balance at end of the year $ 560 $ 992 There were no transfers to Level 3 during the twelve months ended November 30, 2014.

RESEARCH AND DEVELOPMENT EXPENS

RESEARCH AND DEVELOPMENT EXPENSES, net	12 Months Ended
	Nov. 30, 2015
RESEARCH AND DEVELOPMENT EXPENSES, net [Text Block]	NOTE 15 – RESEARCH AND DEVELOPMENT EXPENSES, NET Year Ended November 30, 2015 2014 (in thousands) Total expenses $ 1,860 $ 2,478 Less grant (793 ) (929 ) Total $ 1,067 $ 1,549

FINANCIAL EXPENSES (INCOMES), N

FINANCIAL EXPENSES (INCOMES), NET	12 Months Ended
	Nov. 30, 2015
FINANCIAL EXPENSES (INCOMES), NET [Text Block]	NOTE 16 – FINANCIAL EXPENSES (INCOME), NET Year Ended November 30, 2015 2014 (in thousands) Decrease in fair value of warrants and financial liabilities measured at fair value $ (2,596 ) $ (180 ) Interest expense on convertible loans 726 691 Funding fees 135 Foreign exchange loss, net 50 10 Issuance of warrants as induced conversion 260 Other expenses (30 ) 11 Total $ (1,850 ) $ 927

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Nov. 30, 2015
RELATED PARTY TRANSACTIONS [Text Block]	NOTE 17 - RELATED PARTY TRANSACTIONS November 30, 2015 2014 (in thousands) Management and consulting fees to the Chairman of the Board $ 57 $ 34 Compensation to the nonexecutive directors (except the Chairman of the Board) $ 71 $ 39 Convertible loan from a related Fund* $ 350 $ * The convertible loan was granted with the same terms as the convertibles loans from third parties

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Nov. 30, 2015
SUBSEQUENT EVENTS [Text Block]	NOTE 18 - SUBSEQUENT EVENTS a. On December 7, 2015 and December 21, 2015, the Company entered into definitive agreements with accredited investors relating to a private placement of (i) 240,385 shares of the Company’s common stock and (ii) three year warrants to purchase up to an additional 240,385 shares of the Company’s common stock at a per share exercise price of $0.52. The purchased securities were issued pursuant to subscription agreements between the Company and the purchasers for aggregate proceeds to the Company of $125 thousand. c. On February 18, 2016, the Israeli subsidiary entered into a Collaboration Agreement with Grand China Energy Group Limited with headquarters in Beijing, China (“Grand China”) to collaborate in carrying out clinical trials and marketing the Company’s autologous insulin producing cell therapy product (“API”) in the Peoples Republic of China, Hong Kong and Macau (the “Territory”), based on achieving certain pre-market development milestones. Upon achieving the pre-market development milestones by Grand China, the parties will collaborate on marketing the products in the Territory. Grand China will bear all costs associated with the pre-marketing development efforts in the Territory. Subject to the completion of the pre-marketing development milestones, the Israeli subsidiary has agreed to grant to Grand China, or a fully owned subsidiary thereof, under a separate sub-license agreement to the intellectual property underlying the API solely for commercialization of the Company’s products in the Territory. Grand China has agreed to pay annual license fees, ongoing royalties based on net sales generated by Grand China and its sublicensees, milestone payments and sublicense fees.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Nov. 30, 2015
Use of Estimates in the Preparation of Financial Statements [Policy Text Block]	a. Use of Estimates in the Preparation of Financial Statements The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statement date and the reported expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to the valuation of stock based compensation, valuation of financial instruments measured at fair value and valuation of intangible assets.
Business Combination [Policy Text Block]	b. Business Combination The Company allocates the purchase price of an acquired business to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Acquired in-process backlog, customer relations, brand name and know how are recognized at fair value. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets. Direct transaction costs associated with the business combination are expensed as incurred. The allocation of the consideration transferred in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The Company includes the results of operations of the business that it has acquired in its consolidated results prospectively from the date of acquisition.
Cash equivalents [Policy Text Block]	c. Cash equivalents The Company considers all short term, highly liquid investments, which include short term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.
Restricted Cash [Policy Text Block]	d. Restricted Cash The company has restricted cash deposited as a guarantee for the use of the Company's credit card. The Company classifies these amounts as a non-current asset since the Company expects to continue the use of the credit card.
Research and Development [Policy Text Block]	e. Research and Development, net Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, stock-based compensation expenses, payroll taxes and other employees' benefits, lab expenses, consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred. Participation from government departments and from research foundations for development of approved projects is recognized as a reduction of expense as the related costs are incurred.
Principles of Consolidation [Policy Text Block]	f. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned Subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Functional Currency [Policy Text Block]	g. Functional Currency The currency of the primary economic environment in which the operations of the Company and part of its Subsidiaries are conducted is in U.S. dollars (“$” or “dollar”). The functional currency of the Belgian Subsidiaries is the Euro (“€” or “Euro”). Most of the Company’s expenses are incurred in dollars and the source of the Company’s financing has been provided in dollars. Thus, the functional currency of the Company and its Subsidiaries is the dollar. Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for nonmonetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions – exchange rates at transaction dates or average rates and (2) for other items (derived from nonmonetary balance sheet items such as depreciation) – historical exchange rates. The resulting transaction gains or losses are recorded as financial income or expenses. The financial statements of the Belgian Subsidiaries are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated at yearly average exchange rates during the year. Differences resulting from translation of assets and liabilities are presented as other comprehensive income.
Inventory [Policy Text Block]	h. Inventory Inventory is stated at the lower of cost or net realizable value with cost determined under the first-in-first-out (FIFO) cost method. The entire balance of inventory at November 30, 2015, consists of raw material.
Property and Equipment [Policy Text Block]	i. Property and Equipment Property and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the related assets. Annual rates of depreciation are presented in the table below: Weighted Average Useful Life (Years) Production facility 10 Laboratory equipment 5 Office equipment and computers 3 - 5
Intangible Assets [Policy Text Block]	j. Intangible Assets Intangible assets and their useful lives are as follows: Weighted Average Amortization Recorded at Useful Life (Years) Comprehensive Loss Line Item Backlog 1.75 Cost of revenues Customer Relationships 7.75 Amortization of intangible assets Brand 9.75 Amortization of intangible assets Know-How 11.75 Amortization of intangible assets Intangible assets are recorded at acquisition cost less accumulated amortization and impairment. Definite lived intangible assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over which the cash flows from the asset are expected to be generated.
Goodwill [Policy Text Block]	k. Goodwill Goodwill represents the excess of the purchase price of acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least annually (at November 30), at the reporting unit level or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test is applied by performing a qualitative assessment before calculating the fair value of the reporting unit. If, on the basis of qualitative factors, it is considered not more likely than not that the fair value of the reporting unit is less than the carrying amount, further testing of goodwill for impairment would not be required. Otherwise, goodwill impairment is tested using a two-step approach. The first step involves comparing the fair value of the reporting unit to its carrying amount. If the fair value of the reporting unit is determined to be greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount is determined to be greater than the fair value, the second step must be completed to measure the amount of impairment, if any. The second step involves calculating the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit from the fair value of the reporting unit as determined in step one. The implied fair value of the goodwill in this step is compared to the carrying value of goodwill. If the implied fair value of the goodwill is less than the carrying value of the goodwill, an impairment loss equivalent to the difference is recorded.
Impairment of Long-lived Assets [Policy Text Block]	l. Impairment of Long-lived Assets The Company reviews its property and equipment, intangible assets subject to amortization and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset class may not be recoverable. Indicators of potential impairment include: an adverse change in legal factors or in the business climate that could affect the value of the asset; an adverse change in the extent or manner in which the asset is used or is expected to be used, or in its physical condition; and current or forecasted operating or cash flow losses that demonstrate continuing losses associated with the use of the asset. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted cash flows. There were no impairment charges in 2015.
Revenue Recognition [Policy Text Block]	m. Revenue Recognition The Company recognizes revenue for services linked to cell process development and cell manufacturing services based on individual contracts in accordance with ASC 605, Revenue Recognition, The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform. Cell manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met. For service agreement contracts where the Company is delivering services by executing more than one act, revenue is recognised based on the proportional performance method. Under this method, the costs are recognised in the income statement as incurred and the revenue recognized will be a proportion of the total contract consistent with the costs proportion of total costs. Any amounts invoiced to clients as a result of contractual terms are recognized as deferred income to the extent it exceeds the performance completed. The Company also incurs revenue of some consumables which are incidental to the services provided as foreseen in the clinical services contracts. The Company bills customers for reimbursable expenses and immediately recognizes these billings in revenue, as the revenue is deemed earned.
Financial Liabilities Measured at Fair Value [Policy Text Block]	n. Financial Liabilities Measured at Fair Value 1) Fair Value Option Topic 815 provides entities with an option to report certain financial assets and liabilities at fair value with subsequent changes in fair value reported in earnings. The election can be applied on an instrument by instrument basis. The Company elected the fair value option to its convertible bonds. The liability is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net (See also Note 14). 2) Warrants and Price Protection Mechanism Derivative Classified as a Liability Warrants that entitle the holder to down-round protection (through ratchet and anti-dilution provisions) and price protection mechanism derivatives in respect of shares entitled to down-round protection are classified as liabilities on the balance sheet. The liability is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net (See Note 14). 3) Derivatives Embedded derivatives are separated from the host contract and carried at fair value when (1) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract and (2) a separate, standalone instrument with the same terms would qualify as a derivative instrument. The derivative is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net. As to embedded derivatives arising from the issuance of convertible debentures, see Note 14.
Income Taxes [Policy Text Block]	o. Income Taxes 1) With respect to deferred taxes, income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. 2) The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained on examination. If this threshold is met, the second step is to measure the tax position as the largest amount that is greater than 50% likely of being realized upon ultimate settlement. 3) Taxes that would apply in the event of disposal of investment in Subsidiaries have not been taken into account in computing the deferred income taxes, as it is the Company’s intention to hold these investments and not realize them.
Stock-Based Compensation [Policy Text Block]	p. Stock-based Compensation The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718, Compensation - Stock Compensation The Company follows ASC Topic 505-50, Equity-Based Payments to Non-Employees
Redeemable Common Stock [Policy Text Block]	q. Redeemable Common Stock Common stock with embedded redemption features, such as an unwind option, whose settlement is not at the Company’s discretion, are considered redeemable common stock. Redeemable common stock is considered to be temporary equity and are therefore presented as a mezzanine section between liabilities and equity on the Company's consolidated balance sheets. Subsequent adjustment of the amount presented in temporary equity is required only if the Company's management estimates that it is probable that the instrument will become redeemable.
Loss per Share of Common Stock [Policy Text Block]	r. Loss per Share of Common Stock Net loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of common shares outstanding during the period. Diluted net loss per share is based upon the weighted average number of common shares and of common shares equivalents outstanding when dilutive. Common share equivalents include: (i) outstanding stock options under the Company’s Global Share Incentive Plan (2012) and warrants which are included under the treasury share method when dilutive, and (ii) common shares to be issued under the assumed conversion of the Company’s outstanding convertible debentures, which are included under the if-converted method when dilutive. The computation of diluted net loss per share for the year ended November 30, 2015 includes common share equivalents due to warrants (See Note 11).
Concentration of Credit Risk [Policy Text Block]	s. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, restricted cash and certain receivables. The Company held these instruments with highly rated financial institutions and the Company has not experienced any credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments. There is no bad debt allowance provided to date.
Beneficial Conversion Feature (BCF) [Policy Text Block]	t. Beneficial Conversion Feature (“BCF”) When the Company issues convertible debt, if the stock price is greater than the effective conversion price (after allocation of the total proceeds) on the measurement date, the conversion feature is considered "beneficial" to the holder. If there is no contingency, this difference is treated as issued equity and reduces the carrying value of the host debt; the discount is accreted as deemed interest on the debt (See Note 7).
Other Comprehensive Loss [Policy Text Block]	u. Other Comprehensive Loss Other comprehensive loss represents adjustments of foreign currency translation.
Newly Issued Accounting Pronouncements [Policy Text Block]	v. Newly Issued Accounting Pronouncements In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements— Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. Continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Prior to this, there was no guidance under U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this update provide that guidance. In doing so, the amendments reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term “substantial doubt”, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). For the period ended November 30, 2015, management evaluated the Company’s ability to continue as a going concern and concluded that substantial doubt has not been alleviated about the Company’s ability to continue as a going concern. While the Company continues to explore further significant sources of financing, management’s assessment was based on the uncertainty related to the availability amount and nature of such financing over the next twelve months. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09) "Revenue from Contracts with Customers." ASU 2014-09 will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2016 (early adoption is not permitted). The guidance permits the use of either a retrospective or cumulative effect transition method. On July 9, 2015, the FASB decided to delay the effective date of the new revenue standard by one year. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The Company is currently evaluating the impact of this standard. In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2015-11 (ASU 2015-11), Simplifying the Measurement of Inventory During November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognise leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN26

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Nov. 30, 2015
Schedule of Annual Depreciation Rates, Property and Equipment [Table Text Block]	Weighted Average Useful Life (Years) Production facility 10 Laboratory equipment 5 Office equipment and computers 3 - 5
Schedule of Intangible Assets, Useful Lives [Table Text Block]	Weighted Average Amortization Recorded at Useful Life (Years) Comprehensive Loss Line Item Backlog 1.75 Cost of revenues Customer Relationships 7.75 Amortization of intangible assets Brand 9.75 Amortization of intangible assets Know-How 11.75 Amortization of intangible assets

ACQUISITION OF MASTHERCELL (Tab

ACQUISITION OF MASTHERCELL (Tables)	12 Months Ended
	Nov. 30, 2015
Schedule of Total Consideration Transferred [Table Text Block]	Total purchase consideration: Redeemable common stock $ 24,592 Less convertible bonds 3,134 Total fair value of consideration transferred $ 21,458
Schedule of Allocation of Purchase Price to Fair Value of the Assets Acquired and Liabilities Assumed [Table Text Block]	Total assets acquired: Cash and cash equivalents $ 305 Property and equipment 4,236 Inventory 231 Other current assets 1,664 Other intangible assets 18,977 Goodwill 10,106 Total assets 35,519 Total liabilities assumed: Deferred income 947 Deferred taxes 4,440 Loan payables 6,998 Other liabilities 1,676 Total liabilities 14,061 Total consideration transferred $ 21,458
Schedule of Supplemental Pro Forma Results of Operations [Table Text Block]	Year Ended November 30, 2015 2014 (in thousands) Revenue $ 3,886 $ 1,606 Net loss $ 5,558 $ 9,573 Net loss per common share: Basic $ 0.10 $ 0.18 Diluted $ 0.13 $ 0.21
Schedule of Adjustments to Supplemental Pro Forma Results of Operations [Table Text Block]	Year Ended November 30, 2015 2014 (in thousands) Amortization of intangibles $ 471 $ 2,124 Deferred income 88 400 Deferred tax (183 ) (354 ) Transaction costs (258 ) 258 Interest on convertible bonds (21 ) (1,483 ) Total $ 97 $ 945

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Nov. 30, 2015
Schedule of Segment Information [Table Text Block]	Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 3,320 $ $ (346 ) $ 2,974 Cost of revenues (3,099 ) (3,099 ) Research and development expenses, net (1,279 ) 346 (933 ) Operating expenses (1,304 ) (1,799 ) (3,103 ) Depreciation and amortization expense (1,984 ) (5 ) (1,989 ) Adjusted EBIT $ (3,067 ) $ (3,083) (6,150 ) Share-based compensation (803 ) (803 ) Acquistion costs (258 ) (258 ) Financial income 1,850 1,850 Loss before income tax (5,361 )
Schedule of Revenues from Major Customers [Table Text Block]	Year Ended November 30, 2015 (in thousands) Customer A $ 1,921 Customer B $ 626

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Nov. 30, 2015
Schedule of Property, Plant and Equipment [Table Text Block]	November 30, 2015 2014 (in thousands) Cost: Production facility $ 3,638 $ - Office furniture and computers 120 16 Lab equipment 1,200 6 4,958 22 Less – accumulated depreciation (662 ) (9 ) Total $ 4,296 $ 13

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL (Tables)	12 Months Ended
	Nov. 30, 2015
Schedule of Goodwill [Table Text Block]	November 30, 2015 (in thousands) Goodwill as of December 1, 2014 $ - Goodwill as acquired 10,106 Translation differences (571 ) Goodwill as of November 30,2015 $ 9,535
Schedule of Intangible Assets [Table Text Block]	November 30, 2015 (In thousands) Gross Carrying Amount: Know How $ 16,073 Backlog 237 Customer relationships 330 Brand name 1,266 17,906 Accumulated amortization 1,253 Net carrying amount of other intangible assets $ 16,653
Schedule of Intangible Assets, Future Amortization Expense [Table Text Block]	2016 2017 to 2020 (in thousands) Amortization expenses $ 1,744 $ 1,608

CONVERTIBLE LOAN AGREEMENTS (Ta

CONVERTIBLE LOAN AGREEMENTS (Tables)	12 Months Ended
	Nov. 30, 2015
Schedule of Fair Value of Instruments as of Closing Date [Table Text Block]	Total Fair Allocation of Value Proceeds (in thousands) Loan component $ 1,262 $ 746 Shares component 250 180 Embedded derivative component 574 574 Total $ 2,086 $ 1,500
Schedule of Convertible Debt [Table Text Block]	Grant Date Maturity Date November 30, 2015 (in thousands) Convertible loan a June 9, 2015 December 9, 2015 $50 Convertible loan b June 16, 2015 December 16, 2015 250 Convertible loan c June 24, 2015 December 31, 2015 350 Convertible loan d October 15, 2015 October 15, 2016 50 Convertible loan e October 27, 2015 April 27, 2016 250 $950

LOANS (Tables)

LOANS (Tables)	12 Months Ended
	Nov. 30, 2015
Schedule of Long-term Debt Instruments [Table Text Block]	Interest Rate Loan Amount November 30, Year of November 30, (in thousands) Grant Date 2015 Maturity 2015 (in thousands) Long-term loan a (*) € 1,400 August 1, 2012 4.05% 2022 $ 1,086 Long-term loan b € 1,000 August 13, 2012 6% - 7.5% 2023 1,089 Long-term loan c € 250 August 6, 2012, 6% 2022 205 Long-term loan d € 250 February 10, 2014 5.5% 2024 247 Long-term loan e € 290 April 23, 2015 5.5% 2020 350 Long-term loan f € 800 February 21, 2014 Euribord + 2% 2016 529 $ 3,506 Current portion of loans payable 966 $ 2,540
Schedule of Short-term Debt [Table Text Block]	Amount in the Interest Rate Currency of November 30, November 30, Loan 2015 2015 (in thousands) Current portion of loans payable a Euro 4.05% $ 139 Current portion of loans payable b Euro 6% - 7.5% 166 Current portion of loans payable c Euro 6% 54 Current portion of loans payable d Euro 5.5% 35 Current portion of loans payable e Euro 5.5% 43 Current portion of loans payable f Euro Euribord + 2% 529 $ 966 Short term-loans* Euro 7% 1,334 Short term-loan** Euro 6.3% 529 $ 2,829

CAPITAL DEFICIENCY (Tables)

CAPITAL DEFICIENCY (Tables)	12 Months Ended
	Nov. 30, 2015
Schedule of Fair Value of Instruments for Financing [Table Text Block]	Total Fair Value (in thousands) Warrants component $ 1,390 Price protection derivative component 1,529 Shares component 1,284 Total $ 4,203
Schedule of Fair Value of Private Placements [Table Text Block]	Exercise Price / Number of Adjusted Number of Issuance Warrants Exercise Expiration Warrants Date Issued Price Date Outstanding October 27, 2015 192,308 $0.40 March 27, 2018 192,308 November 30, 2015 7,891,108 $0.40 November 30, 2018 7,891,108 8,083,416 8,083,416
Schedule of Fair Value of Warrants [Table Text Block]	Exercise Price / Number of Adjusted Number of Grant Warrants Exercise Expiration Warrants Date Issued Price Date Outstanding March 2014 713,023 $0.52 March 2017 713,023 April 2014 384,615 $0.52 April 2017 384,615 July 2014 192,308 $0.52 July 2017 192,308 July 2014 144,230 $0.52 July 2017 144,230 August 2014 115,385 $0.52 August 2017 115,385 October 2015 2,358,490 $0.53 October 2018 2,358,490 3,908,051 3,908,051

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	12 Months Ended
	Nov. 30, 2015
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended November 30, 2015 2014 (in thousands, except per share data) Basic: Loss for the year $ 4,461 $ 5,504 Weighted average number of common shares outstanding 55,798,416 54,162,596 Loss per common share $ 0.08 $ 0.10 Diluted Loss for the year $ 4,461 5,504 Changes in fair value of embedded derivative and interest expenses on convertible bonds 1,272 Change in fair value of warrants 559 598 Loss for the year $ 6,292 6,102 Weighted average number of shares used in the computation of basic loss per share 55,798,416 54,162,596 Number of dilutive shares related to convertible bonds 873,380 Number of dilutive shares related to warrants 249,116 559,373 Weighted average number of common shares outstanding 56,920,912 54,721,969 Loss per common share $ 0.11 $ 0.11

STOCK BASED COMPENSATION (Table

STOCK BASED COMPENSATION (Tables)	12 Months Ended
	Nov. 30, 2015
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended November 30, 2015 2014 Value of one common share $0.53 $0.53 - 0.63 Dividend yield 0% 0% Expected stock price volatility 85.7% 100.5 - 100.6% Risk free interest rate 1.68% 1.67 - 2.52% Expected term (years) 2.5 5 - 10
Schedule of Stock Options Granted to Employees and Directors [Table Text Block]	2015 2014 Weighted Weighted Average Average Exercise Exercise Number of Price Number of Price Options $ Options $ Options outstanding at the beginning of the year 12,809,455 0.27 12,294,765 0.265 Changes during the year: Granted 500,000 0.53 2,707,300 0.194 Exercised (623,806 ) 0.001 Expired (2,440,120 ) 0.68 Forfeited (528,125 ) 0.5 (1,568,804 ) 0.205 Options outstanding at end of the year 10,341,210 0.16 12,809,455 0.27 Options exercisable at end of the year 8,696,162 0.09 9,661,548 0.568
Schedule of Information Stock Options Granted to Employees and Directors [Table Text Block]	Weighted Weighted Average Average Aggregate Exercise Number of Remaining Exercise Intrinsic Prices Outstanding Contractual Price Value $ Options Life $ $ (in thousands) 0.0001 4,439,205 7.1 0.0001 1,464 0.001 3,338,285 6.2 0.001 1,098 0.50 400,000 8.7 0.5 0.53 500,000 9.5 0.53 0.75 250,000 7.6 0.75 0.79 942,520 6.6 0.79 0.85 471,200 6.5 0.85 0.17 10,341,210 6.9 1.016 2,562
Schedule of Disclosure of Share-based Compensation Stock Options Exercisable [Table Text Block]	Exercise Number of Prices Exercisable $ Options Total (in thousands) 0.0001 3,584,645 0.3 0.001 3,338,285 3 0.50 325,000 163 0.53 500,000 265 0.75 100,000 75 0.79 565,512 447 0.85 282,720 240 8,696,162 1,193
Schedule of Fair Value of Stock Options Granted Valuation Assumptions [Table Text Block]	Year Ended November 30, 2014 Value of one common share $0.51 Dividend yield 0% Expected stock price volatility 100% Risk free interest rate 0.11 - 0.95% Expected term (years) 1 - 3
Schedule of Fair Value of Stock Options Granted Valuation Assumptions By Using Hybrid Model[Table Text Block]	Year Ended November 30, 2015 2014 Value of one common share $0.65, 0.53 $0.53 Dividend yield 0% 0% Expected stock price volatility 86%, 89% 101% Risk free interest rate 1.34%, 1.42% 1.31% Expected term (years) 5 4
Schedule of Stock Options Granted to Non-Employees [Table Text Block]	2015 2014 Weighted Weighted Average Average Exercise Exercise Number of Price Number of Price Options $ Options $ Options outstanding at the beginning of the year 2,458,104 0.75 1,378,104 0.95 Changes during the year: Granted 200,000 0.51 2,080,000 0.51 Expired (1,000,000 ) 0.52 Options outstanding at end of the year 2,658,104 0.75 2,458,104 0.75 Options exercisable at end of the year 1,521,624 0.65 1,171,384 0.77
Schedule of Information Options Granted to Non-Employees [Table Text Block]	Weighted Weighted Average Average Aggregate Exercise Number of Remaining Exercise Instrinsic Prices Outstanding Contractual Price Value* $ Options Life $ $ 0.50 1,080,000 2.67 0.50 0.52 100,000 4.55 0.52 0.61 100,000 6.98 0.61 0.65 100,000 4.2 0.65 0.69 706,904 6.17 0.69 0.96 100,000 7.35 0.96 1.40 471,200 6.38 1.40 2,658,104 4.72 0.75 -
Schedule of Stock Options Exercisable [Table Text Block]	Exercise Number of Total Prices Exercisable Exercise $ Options Value $ 0.50 432,000 216 0.61 60,000 37 0.69 706,904 488 0.96 40,000 38 1.40 282,720 396 1,521,624 1,175

TAXES (Tables)

TAXES (Tables)	12 Months Ended
	Nov. 30, 2015
Schedule of Deferred Tax Assets [Table Text Block]	November 30, 2015 2014 (U.S dollars in thousands) Net operating loss carry forwards $ 5,658 $ 1,626 Research and development expenses (178 ) 230 Employee benefits 31 14 Property and equipment 268 Convertible bonds 45 Deferred income (508 ) Intangible assets (5,661 ) Less: Valuation allowance (2,982 ) (1,870 ) Net deferred tax liabilities $ (3,327 ) $ -
Schedule of Valuation Allowance, Activity [Table Text Block]	Year Ended November 30, 2015 2014 (U.S dollars in thousands) Balance at the beginning of year $ (1,870 ) $ (1,212 ) Additions during the year (1,112 ) (658 ) Balance at end of year $ (2,982 ) $ (1,870 )

FAIR VALUE PRESENTATION (Tables

FAIR VALUE PRESENTATION (Tables)	12 Months Ended
	Nov. 30, 2015	Nov. 30, 2014
Schedule of Assets and Liabilities at Fair Value [Table Text Block]	November 30, November 30, 2015 2014 Level 3 Level 3 Warrants (1) $ 1,382 $ 560 Price protection derivative (1) 1,533 Embedded derivatives*(1) 289 992 Convertible bonds (2) $ 1,888 $
Schedule of Fair Value, Assumptions Used [Table Text Block]	Price Protection Derivative and Embedded Convertible Warrants Derivative Bonds Fair value of shares of common stock $ 0.33 $ 0.33 $ 0.33 Expected volatility 87%- 98% 87% 88% Discount on lack of marketability 14% - 18% Risk free interest rate 0.44%- 1.24% 0.11%-0.49% 0.42% Expected term (years) 2.9 - 3 0.08 - 0.87 0.8 Expected dividend yield 0% 0% 0% Expected capital raise dates Q2 2016-Q4 2016, Q4 2017	Embedded Warrants Derivative Value of one common share $0.65 $0.65 Dividend yield 0% 0% Expected stock price volatility 100% 100% Risk free interest rate 0.03 – 0.11% 0.04% Expected term (years) 0.3 – 0.8 0.08 Expected capital raise dates March 2015 March 2015
Schedule of Sensitivity Analysis of Fair Value, Warrants [Table Text Block]	Base -10% Base Base+10% (in thousands) As of November 30, 2015 $ 1,263 $ 1,382 $ 1,486
Schedule of Sensitivity Analysis of Changes in Fair Value, Derivatives [Table Text Block]	Base -10% Base Base+10% (in thousands) As of November 30, 2015 $ 1,502 $ 1,533 $ 1,552
Schedule of Sensitivity Analysis of Changes in Fair Value, Convertible Bonds [Table Text Block]	Base -5% Base Base+5% (in thousands) As of November 30, 2015 $ 1,885 $ 1,888 $ 1,920
Schedule of Fair Value of Financial Liabilities, Activity [Table Text Block]	Price Embedded Convertible Protection Warrants Derivatives Bonds Derivative (in thousands) Balance at beginning of the year $ 560 $ 992 $ - $ - Additions 1,390 112 3,234 1,526 Changes in fair value related to warrants expired* (525 ) - 7 Changes in fair value during the period (43 ) (815 ) (1,221 ) Translation adjustments - - (125 ) Balance at end of the year $ 1,382 $ 289 $ 1,888 $ 1,533	Embedded Warrants Derivatives (in thousands) Balance at beginning of the year Additions $ 1,158 $ 574 Changes in fair value during the year (348 ) 418 Changes in fair value related to warrants expired (250 ) Balance at end of the year $ 560 $ 992

RESEARCH AND DEVELOPMENT EXPE38

RESEARCH AND DEVELOPMENT EXPENSES, net (Tables)	12 Months Ended
	Nov. 30, 2015
Schedule of Research and Development Expenses [Table Text Block]	Year Ended November 30, 2015 2014 (in thousands) Total expenses $ 1,860 $ 2,478 Less grant (793 ) (929 ) Total $ 1,067 $ 1,549

FINANCIAL EXPENSES (INCOMES),39

FINANCIAL EXPENSES (INCOMES), NET (Tables)	12 Months Ended
	Nov. 30, 2015
Schedule of Financial Expenses [Table Text Block]	Year Ended November 30, 2015 2014 (in thousands) Decrease in fair value of warrants and financial liabilities measured at fair value $ (2,596 ) $ (180 ) Interest expense on convertible loans 726 691 Funding fees 135 Foreign exchange loss, net 50 10 Issuance of warrants as induced conversion 260 Other expenses (30 ) 11 Total $ (1,850 ) $ 927

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Nov. 30, 2015
Schedule of Related Party Transactions [Table Text Block]	November 30, 2015 2014 (in thousands) Management and consulting fees to the Chairman of the Board $ 57 $ 34 Compensation to the nonexecutive directors (except the Chairman of the Board) $ 71 $ 39 Convertible loan from a related Fund* $ 350 $

GENERAL AND BASIS OF PRESENTA41

GENERAL AND BASIS OF PRESENTATION (Narrative) (Details) $ in Millions	12 Months Ended
	Nov. 30, 2015USD ($)
General And Basis Of Presentation 1	$ 20.6

SUMMARY OF SIGNIFICANT ACCOUN42

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	12 Months Ended
	Nov. 30, 2015
Summary Of Significant Accounting Policies 1	50.00%

ACQUISITION OF MASTHERCELL (Nar

ACQUISITION OF MASTHERCELL (Narrative) (Details) - 12 months ended Nov. 30, 2015 $ / shares in Units, € in Millions	USD ($)moyr$ / sharesshares	EUR (€)moyrshares
Acquisition Of Masthercell 1 | shares	42,401,724	42,401,724
Acquisition Of Masthercell 2 | $ / shares	$ 0.58
Acquisition Of Masthercell 3	$ 24,593,000
Acquisition Of Masthercell 4 | shares	8,173,483	8,173,483
Acquisition Of Masthercell 5	$ 3,000,000
Acquisition Of Masthercell 6	2,300,000
Acquisition Of Masthercell 7	10,000,000
Acquisition Of Masthercell 8	$ 45,000,000
Acquisition Of Masthercell 9	3,800,000	3,800,000
Acquisition Of Masthercell 10	1,200,000	1,200,000
Acquisition Of Masthercell 11	$ 10,000,000
Acquisition Of Masthercell 12 | shares	8,227,647	8,227,647
Acquisition Of Masthercell 13 | $ / shares	$ 0.0001
Acquisition Of Masthercell 14 | shares	8,227,647	8,227,647
Acquisition Of Masthercell 15	$ 0.52
Acquisition Of Masthercell 16	4,278,000
Acquisition Of Masthercell 17 | €		€ 3.8
Acquisition Of Masthercell 18	$ 4,103,000
Acquisition Of Masthercell 19 | €		5
Acquisition Of Masthercell 20 | €		2.2
Acquisition Of Masthercell 21 | €		1
Acquisition Of Masthercell 22 | €		€ 1.6
Acquisition Of Masthercell 23	3.00%	3.00%
Acquisition Of Masthercell 24	0.36	0.36
Acquisition Of Masthercell 25 | mo	14	14
Acquisition Of Masthercell 26	8,173,483	8,173,483
Acquisition Of Masthercell 27 | mo	14	14
Acquisition Of Masthercell 28	$ 349,000
Acquisition Of Masthercell 29	17,037,000
Acquisition Of Masthercell 30	250,000
Acquisition Of Masthercell 31	$ 1,341,000
Acquisition Of Masthercell 32	1.75	1.75
Acquisition Of Masthercell 33 | yr	11.75	11.75
Acquisition Of Masthercell 34	$ 258,000

SEGMENT INFORMATION (Narrative)

SEGMENT INFORMATION (Narrative) (Details)	12 Months Ended
	Nov. 30, 2015
Segment Information 1	1
Segment Information 2	10.00%

PROPERTY AND EQUIPMENT (Narrati

PROPERTY AND EQUIPMENT (Narrative) (Details) $ in Thousands	12 Months Ended
	Nov. 30, 2015USD ($)
Property And Equipment 1	$ 681
Property And Equipment 2	$ 4

INTANGIBLE ASSETS AND GOODWIL46

INTANGIBLE ASSETS AND GOODWILL (Narrative) (Details) $ in Millions	12 Months Ended
	Nov. 30, 2015USD ($)
Intangible Assets And Goodwill 1	3.00%
Intangible Assets And Goodwill 2	17.20%
Intangible Assets And Goodwill 3	1.00%
Intangible Assets And Goodwill 4	1.00%
Intangible Assets And Goodwill 5	$ 2.9
Intangible Assets And Goodwill 6	3.4
Intangible Assets And Goodwill 7	$ 1.3

CONVERTIBLE LOAN AGREEMENTS (Na

CONVERTIBLE LOAN AGREEMENTS (Narrative) (Details)	12 Months Ended
	Nov. 30, 2015USD ($)$ / sharesshares
Convertible Loan Agreements 1	$ 1,500,000
Convertible Loan Agreements 2	8.00%
Convertible Loan Agreements 3 | $ / shares	$ 0.40
Convertible Loan Agreements 4 | shares	500,000
Convertible Loan Agreements 5	$ 0.50
Convertible Loan Agreements 6	$ 0.40
Convertible Loan Agreements 7	94.00%
Convertible Loan Agreements 8	0.05%
Convertible Loan Agreements 9	80.00%
Convertible Loan Agreements 10	$ 150,000
Convertible Loan Agreements 11	6.00%
Convertible Loan Agreements 12 | $ / shares	$ 0.40
Convertible Loan Agreements 13	$ 135,000
Convertible Loan Agreements 14	$ 950,000
Convertible Loan Agreements 15	6.00%
Convertible Loan Agreements 16	75.00%
Convertible Loan Agreements 17	$ 0.40
Convertible Loan Agreements 18	$ 5
Convertible Loan Agreements 19	6,000,000
Convertible Loan Agreements 20	$ 0.52
Convertible Loan Agreements 21	0.52
Convertible Loan Agreements 22	$ 0.52

LOANS (Narrative) (Details)

LOANS (Narrative) (Details) € in Thousands	12 Months Ended
	Nov. 30, 2015EUR (€)
Loans 1	€ 1,400
Loans 2	€ 1,247
Loans 3	7.00%
Loans 4	€ 500

COMMITMENTS (Narrative) (Detail

COMMITMENTS (Narrative) (Details) - 12 months ended Nov. 30, 2015 $ in Thousands	USD ($)moyrshares	EUR (€)moyrshares
Commitments 1	3.50%	3.50%
Commitments 2	16.00%	16.00%
Commitments 3	$ 15
Commitments 4	50
Commitments 5	50
Commitments 6	150
Commitments 7	750
Commitments 8	2,000
Commitments 9	$ 150,000
Commitments 10 | shares	5,563,809	5,563,809
Commitments 11 | shares	1,000	1,000
Commitments 12	$ 92
Commitments 13	110
Commitments 14	642
Commitments 15	460
Commitments 16	406
Commitments 17	203
Commitments 18	203
Commitments 19	11
Commitments 20 | €		€ 2,015,000
Commitments 21	$ 2,400
Commitments 22	1	1
Commitments 23 | €		€ 1,085,000
Commitments 24	70.00%	70.00%
Commitments 25 | €		€ 930,000
Commitments 26	60.00%	60.00%
Commitments 27 | yr	3	3
Commitments 28	16	16
Commitments 29 | €		€ 651,000
Commitments 30 | €		558,000
Commitments 31	$ 1,400
Commitments 32 | €		1,100,000
Commitments 33	$ 114
Commitments 34 | €		€ 1,421,000
Commitments 35	32.00%	32.00%
Commitments 36 | €		€ 568,000
Commitments 37	$ 400
Commitments 38	5.00%	5.00%
Commitments 39 | mo	18	18
Commitments 40	$ 153
Commitments 41	$ 100
Commitments 42 | yr	12	12
Commitments 43 | €		€ 28,000
Commitments 44	$ 30
Commitments 45	120,000	120,000
Commitments 46	$ 31

CAPITAL DEFICIENCY (Narrative)

CAPITAL DEFICIENCY (Narrative) (Details)	12 Months Ended
	Nov. 30, 2015USD ($)$ / sharesshares
Capital Deficiency 1 | shares	1,773,079
Capital Deficiency 2 | $ / shares	$ 0.52
Capital Deficiency 3	$ 922,000
Capital Deficiency 4 | $ / shares	$ 0.52
Capital Deficiency 5	$ 625,000
Capital Deficiency 6	0.00%
Capital Deficiency 7	101.00%
Capital Deficiency 8	117.00%
Capital Deficiency 9	0.68%
Capital Deficiency 10	0.95%
Capital Deficiency 11	$ 24,000
Capital Deficiency 12	46,175
Capital Deficiency 13	$ 0.52
Capital Deficiency 14	$ 13,000
Capital Deficiency 15 | shares	25,759
Capital Deficiency 16	$ 0.52
Capital Deficiency 17 | shares	96,154
Capital Deficiency 18	$ 0.52
Capital Deficiency 19	$ 50,000
Capital Deficiency 20 | shares	192,308
Capital Deficiency 21 | $ / shares	$ 0.52
Capital Deficiency 22	$ 60,000
Capital Deficiency 23	0.00%
Capital Deficiency 24	103.00%
Capital Deficiency 25	0.98%
Capital Deficiency 26 | shares	8,083,416
Capital Deficiency 27 | shares	8,083,416
Capital Deficiency 28	$ 0.52
Capital Deficiency 29	4,203,000
Capital Deficiency 30	$ 0.52
Capital Deficiency 31 | $ / shares	$ 0.52
Capital Deficiency 32	$ 5,000,000
Capital Deficiency 33	500,000
Capital Deficiency 34	5,000,000
Capital Deficiency 35	$ 10,000,000
Capital Deficiency 36 | shares	2,358,000
Capital Deficiency 37 | $ / shares	$ 0.53
Capital Deficiency 38	0.50
Capital Deficiency 39	$ 0.53
Capital Deficiency 40	$ 5,000,000
Capital Deficiency 41	4,716,980
Capital Deficiency 42	$ 0.09
Capital Deficiency 43	0.00%
Capital Deficiency 44	80.00%
Capital Deficiency 45	0.34%
Capital Deficiency 46	12.00%

LOSS PER SHARE (Narrative) (Det

LOSS PER SHARE (Narrative) (Details)	12 Months Ended
	Nov. 30, 2015shares
Loss Per Share 23	42,401,724
Loss Per Share 24	42,401,724
Loss Per Share 25	12,899,314
Loss Per Share 26	7,546,750
Loss Per Share 27	1,100,000
Loss Per Share 28	15,267,559
Loss Per Share 29	400,000
Loss Per Share 30	2,682,256
Loss Per Share 31	701,796

STOCK BASED COMPENSATION (Narra

STOCK BASED COMPENSATION (Narrative) (Details)	12 Months Ended
	Nov. 30, 2015USD ($)yr$ / sharesshares
Stock Based Compensation 2 | shares	12,000,000
Stock Based Compensation 3 | yr	10
Stock Based Compensation 4 | shares	2,762,250
Stock Based Compensation 5 | $ / shares	$ 0.0001
Stock Based Compensation 6 | shares	414,304
Stock Based Compensation 7	$ 261,000
Stock Based Compensation 8 | shares	1,242,996
Stock Based Compensation 9 | yr	4
Stock Based Compensation 10	$ 783,000
Stock Based Compensation 11 | shares	1,104,950
Stock Based Compensation 12 | shares	500,000
Stock Based Compensation 13 | $ / shares	$ 0.53
Stock Based Compensation 14	$ 136,000
Stock Based Compensation 15	713,000
Stock Based Compensation 16	1,200,000
Stock Based Compensation 17	$ 984,000
Stock Based Compensation 18 | yr	2.73
Stock Based Compensation 19 | shares	3,000,000
Stock Based Compensation 20	1,000,000
Stock Based Compensation 21	2,000,000
Stock Based Compensation 22 | $ / shares	$ 0.52
Stock Based Compensation 23	$ 744,000
Stock Based Compensation 24 | shares	1,080,000
Stock Based Compensation 25	$ 0.50
Stock Based Compensation 26	216,000
Stock Based Compensation 27	216,000
Stock Based Compensation 28	$ 403,000
Stock Based Compensation 29	90
Stock Based Compensation 30	923
Stock Based Compensation 31	$ 260,000
Stock Based Compensation 32 | yr	4.55

TAXES (Narrative) (Details)

TAXES (Narrative) (Details) € in Millions	12 Months Ended
	Nov. 30, 2015USD ($)	Nov. 30, 2015EUR (€)
Taxes 1	35.00%	35.00%
Taxes 2	26.50%	26.50%
Taxes 3	25.00%	25.00%
Taxes 4	34.00%	34.00%
Taxes 5	$ 4,300,000
Taxes 6	138,000
Taxes 7	494,000
Taxes 8	3,200,000
Taxes 9	$ 8,300,000
Taxes 10 | €		€ 7.8

FAIR VALUE PRESENTATION (Narrat

FAIR VALUE PRESENTATION (Narrative) (Details)	12 Months Ended
	Nov. 30, 2015shares
Fair Value Presentation 3	6.00%
Fair Value Presentation 16	1,826,718

SUBSEQUENT EVENTS (Narrative) (

SUBSEQUENT EVENTS (Narrative) (Details) € in Millions	12 Months Ended
	Nov. 30, 2015USD ($)shares	Nov. 30, 2015EUR (€)shares
Subsequent Events 1 | shares	240,385	240,385
Subsequent Events 2 | shares	240,385	240,385
Subsequent Events 3	$ 0.52
Subsequent Events 4	125,000
Subsequent Events 5	$ 4,103,000
Subsequent Events 6 | €		€ 3.8
Subsequent Events 7 | €		€ 5

Schedule of Annual Depreciation

Schedule of Annual Depreciation Rates, Property and Equipment (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Summary Of Significant Accounting Policies Schedule Of Annual Depreciation Rates, Property And Equipment 1	$ 10
Summary Of Significant Accounting Policies Schedule Of Annual Depreciation Rates, Property And Equipment 2	5
Summary Of Significant Accounting Policies Schedule Of Annual Depreciation Rates, Property And Equipment 3	3
Summary Of Significant Accounting Policies Schedule Of Annual Depreciation Rates, Property And Equipment 4	$ 5

Schedule of Intangible Assets,

Schedule of Intangible Assets, Useful Lives (Details)	12 Months Ended
	Nov. 30, 2015
Summary Of Significant Accounting Policies Schedule Of Intangible Assets, Useful Lives 1	1.75
Summary Of Significant Accounting Policies Schedule Of Intangible Assets, Useful Lives 2	7.75
Summary Of Significant Accounting Policies Schedule Of Intangible Assets, Useful Lives 3	9.75
Summary Of Significant Accounting Policies Schedule Of Intangible Assets, Useful Lives 4	11.75

Schedule of Total Consideration

Schedule of Total Consideration Transferred (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Acquisition Of Masthercell Schedule Of Total Consideration Transferred 1	$ 24,592
Acquisition Of Masthercell Schedule Of Total Consideration Transferred 2	3,134
Acquisition Of Masthercell Schedule Of Total Consideration Transferred 3	$ 21,458

Schedule of Allocation of Purch

Schedule of Allocation of Purchase Price to Fair Value of the Assets Acquired and Liabilities Assumed (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Acquisition Of Masthercell Schedule Of Allocation Of Purchase Price To Fair Value Of The Assets Acquired And Liabilities Assumed 1	$ 305
Acquisition Of Masthercell Schedule Of Allocation Of Purchase Price To Fair Value Of The Assets Acquired And Liabilities Assumed 2	4,236
Acquisition Of Masthercell Schedule Of Allocation Of Purchase Price To Fair Value Of The Assets Acquired And Liabilities Assumed 3	231
Acquisition Of Masthercell Schedule Of Allocation Of Purchase Price To Fair Value Of The Assets Acquired And Liabilities Assumed 4	1,664
Acquisition Of Masthercell Schedule Of Allocation Of Purchase Price To Fair Value Of The Assets Acquired And Liabilities Assumed 5	18,977
Acquisition Of Masthercell Schedule Of Allocation Of Purchase Price To Fair Value Of The Assets Acquired And Liabilities Assumed 6	10,106
Acquisition Of Masthercell Schedule Of Allocation Of Purchase Price To Fair Value Of The Assets Acquired And Liabilities Assumed 7	35,519
Acquisition Of Masthercell Schedule Of Allocation Of Purchase Price To Fair Value Of The Assets Acquired And Liabilities Assumed 8	947
Acquisition Of Masthercell Schedule Of Allocation Of Purchase Price To Fair Value Of The Assets Acquired And Liabilities Assumed 9	4,440
Acquisition Of Masthercell Schedule Of Allocation Of Purchase Price To Fair Value Of The Assets Acquired And Liabilities Assumed 10	6,998
Acquisition Of Masthercell Schedule Of Allocation Of Purchase Price To Fair Value Of The Assets Acquired And Liabilities Assumed 11	1,676
Acquisition Of Masthercell Schedule Of Allocation Of Purchase Price To Fair Value Of The Assets Acquired And Liabilities Assumed 12	14,061
Acquisition Of Masthercell Schedule Of Allocation Of Purchase Price To Fair Value Of The Assets Acquired And Liabilities Assumed 13	$ 21,458

Schedule of Supplemental Pro Fo

Schedule of Supplemental Pro Forma Results of Operations (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Acquisition Of Masthercell Schedule Of Supplemental Pro Forma Results Of Operations 1	$ 3,886
Acquisition Of Masthercell Schedule Of Supplemental Pro Forma Results Of Operations 2	1,606
Acquisition Of Masthercell Schedule Of Supplemental Pro Forma Results Of Operations 3	5,558
Acquisition Of Masthercell Schedule Of Supplemental Pro Forma Results Of Operations 4	$ 9,573
Acquisition Of Masthercell Schedule Of Supplemental Pro Forma Results Of Operations 5	0.10
Acquisition Of Masthercell Schedule Of Supplemental Pro Forma Results Of Operations 6	0.18
Acquisition Of Masthercell Schedule Of Supplemental Pro Forma Results Of Operations 7	0.13
Acquisition Of Masthercell Schedule Of Supplemental Pro Forma Results Of Operations 8	0.21

Schedule of Adjustments to Supp

Schedule of Adjustments to Supplemental Pro Forma Results of Operations (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Acquisition Of Masthercell Schedule Of Adjustments To Supplemental Pro Forma Results Of Operations 1	$ 471
Acquisition Of Masthercell Schedule Of Adjustments To Supplemental Pro Forma Results Of Operations 2	2,124
Acquisition Of Masthercell Schedule Of Adjustments To Supplemental Pro Forma Results Of Operations 3	88
Acquisition Of Masthercell Schedule Of Adjustments To Supplemental Pro Forma Results Of Operations 4	400
Acquisition Of Masthercell Schedule Of Adjustments To Supplemental Pro Forma Results Of Operations 5	(183)
Acquisition Of Masthercell Schedule Of Adjustments To Supplemental Pro Forma Results Of Operations 6	(354)
Acquisition Of Masthercell Schedule Of Adjustments To Supplemental Pro Forma Results Of Operations 7	(258)
Acquisition Of Masthercell Schedule Of Adjustments To Supplemental Pro Forma Results Of Operations 8	258
Acquisition Of Masthercell Schedule Of Adjustments To Supplemental Pro Forma Results Of Operations 9	(21)
Acquisition Of Masthercell Schedule Of Adjustments To Supplemental Pro Forma Results Of Operations 10	(1,483)
Acquisition Of Masthercell Schedule Of Adjustments To Supplemental Pro Forma Results Of Operations 11	97
Acquisition Of Masthercell Schedule Of Adjustments To Supplemental Pro Forma Results Of Operations 12	$ 945

Schedule of Segment Information

Schedule of Segment Information (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Segment Information Schedule Of Segment Information 1	$ 3,320
Segment Information Schedule Of Segment Information 2	(346)
Segment Information Schedule Of Segment Information 3	2,974
Segment Information Schedule Of Segment Information 4	(3,099)
Segment Information Schedule Of Segment Information 5	(3,099)
Segment Information Schedule Of Segment Information 6	(1,279)
Segment Information Schedule Of Segment Information 7	346
Segment Information Schedule Of Segment Information 8	(933)
Segment Information Schedule Of Segment Information 9	(1,304)
Segment Information Schedule Of Segment Information 10	(1,799)
Segment Information Schedule Of Segment Information 11	(3,103)
Segment Information Schedule Of Segment Information 12	(1,984)
Segment Information Schedule Of Segment Information 13	(5)
Segment Information Schedule Of Segment Information 14	(1,989)
Segment Information Schedule Of Segment Information 15	(3,067)
Segment Information Schedule Of Segment Information 16	(3,083)
Segment Information Schedule Of Segment Information 17	(6,150)
Segment Information Schedule Of Segment Information 18	(803)
Segment Information Schedule Of Segment Information 19	(803)
Segment Information Schedule Of Segment Information 20	(258)
Segment Information Schedule Of Segment Information 21	(258)
Segment Information Schedule Of Segment Information 22	1,850
Segment Information Schedule Of Segment Information 23	1,850
Segment Information Schedule Of Segment Information 24	$ (5,361)

Schedule of Revenues from Major

Schedule of Revenues from Major Customers (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Segment Information Schedule Of Net Revenues By Customer 1	$ 1,921
Segment Information Schedule Of Net Revenues By Customer 2	$ 626

Schedule of Property, Plant and

Schedule of Property, Plant and Equipment (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Property And Equipment Schedule Of Property, Plant And Equipment 1	$ 3,638
Property And Equipment Schedule Of Property, Plant And Equipment 2	0
Property And Equipment Schedule Of Property, Plant And Equipment 3	120
Property And Equipment Schedule Of Property, Plant And Equipment 4	16
Property And Equipment Schedule Of Property, Plant And Equipment 5	1,200
Property And Equipment Schedule Of Property, Plant And Equipment 6	6
Property And Equipment Schedule Of Property, Plant And Equipment 7	4,958
Property And Equipment Schedule Of Property, Plant And Equipment 8	22
Property And Equipment Schedule Of Property, Plant And Equipment 9	(662)
Property And Equipment Schedule Of Property, Plant And Equipment 10	(9)
Property And Equipment Schedule Of Property, Plant And Equipment 11	4,296
Property And Equipment Schedule Of Property, Plant And Equipment 12	$ 13

Schedule of Goodwill (Details)

Schedule of Goodwill (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Intangible Assets And Goodwill Schedule Of Goodwill 1	$ 0
Intangible Assets And Goodwill Schedule Of Goodwill 2	10,106
Intangible Assets And Goodwill Schedule Of Goodwill 3	(571)
Intangible Assets And Goodwill Schedule Of Goodwill 4	$ 9,535

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Intangible Assets And Goodwill Schedule Of Intangible Assets 1	$ 16,073
Intangible Assets And Goodwill Schedule Of Intangible Assets 2	237
Intangible Assets And Goodwill Schedule Of Intangible Assets 3	330
Intangible Assets And Goodwill Schedule Of Intangible Assets 4	1,266
Intangible Assets And Goodwill Schedule Of Intangible Assets 5	17,906
Intangible Assets And Goodwill Schedule Of Intangible Assets 6	1,253
Intangible Assets And Goodwill Schedule Of Intangible Assets 7	$ 16,653

Schedule of Intangible Assets67

Schedule of Intangible Assets, Future Amortization Expense (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Intangible Assets And Goodwill Schedule Of Intangible Assets, Future Amortization Expense 1	$ 1,744
Intangible Assets And Goodwill Schedule Of Intangible Assets, Future Amortization Expense 2	$ 1,608

Schedule of Fair Value of Instr

Schedule of Fair Value of Instruments as of Closing Date (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Convertible Loan Agreements Schedule Of Fair Value Of Instruments As Of Closing Date 1	$ 1,262
Convertible Loan Agreements Schedule Of Fair Value Of Instruments As Of Closing Date 2	746
Convertible Loan Agreements Schedule Of Fair Value Of Instruments As Of Closing Date 3	250
Convertible Loan Agreements Schedule Of Fair Value Of Instruments As Of Closing Date 4	180
Convertible Loan Agreements Schedule Of Fair Value Of Instruments As Of Closing Date 5	574
Convertible Loan Agreements Schedule Of Fair Value Of Instruments As Of Closing Date 6	574
Convertible Loan Agreements Schedule Of Fair Value Of Instruments As Of Closing Date 7	2,086
Convertible Loan Agreements Schedule Of Fair Value Of Instruments As Of Closing Date 8	$ 1,500

Schedule of Convertible Debt (D

Schedule of Convertible Debt (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Convertible Loan Agreements Schedule Of Convertible Debt 1	$ 50
Convertible Loan Agreements Schedule Of Convertible Debt 2	250
Convertible Loan Agreements Schedule Of Convertible Debt 3	350
Convertible Loan Agreements Schedule Of Convertible Debt 4	50
Convertible Loan Agreements Schedule Of Convertible Debt 5	250
Convertible Loan Agreements Schedule Of Convertible Debt 6	$ 950

Schedule of Long-term Debt Inst

Schedule of Long-term Debt Instruments (Details)	12 Months Ended
	Nov. 30, 2015USD ($)	Nov. 30, 2015EUR (€)
Loans Schedule Of Long-term Debt Instruments 1 | €		€ 1,400
Loans Schedule Of Long-term Debt Instruments 2	4.05%	4.05%
Loans Schedule Of Long-term Debt Instruments 3	$ 1,086
Loans Schedule Of Long-term Debt Instruments 4 | €		€ 1,000
Loans Schedule Of Long-term Debt Instruments 5	6.00%	6.00%
Loans Schedule Of Long-term Debt Instruments 6	7.50%	7.50%
Loans Schedule Of Long-term Debt Instruments 7	$ 1,089
Loans Schedule Of Long-term Debt Instruments 8 | €		€ 250
Loans Schedule Of Long-term Debt Instruments 9	6.00%	6.00%
Loans Schedule Of Long-term Debt Instruments 10	$ 205
Loans Schedule Of Long-term Debt Instruments 11 | €		€ 250
Loans Schedule Of Long-term Debt Instruments 12	5.50%	5.50%
Loans Schedule Of Long-term Debt Instruments 13	$ 247
Loans Schedule Of Long-term Debt Instruments 14 | €		€ 290
Loans Schedule Of Long-term Debt Instruments 15	5.50%	5.50%
Loans Schedule Of Long-term Debt Instruments 16	$ 350
Loans Schedule Of Long-term Debt Instruments 17 | €		€ 800
Loans Schedule Of Long-term Debt Instruments 18	2.00%	2.00%
Loans Schedule Of Long-term Debt Instruments 19	$ 529
Loans Schedule Of Long-term Debt Instruments 20	3,506
Loans Schedule Of Long-term Debt Instruments 21	966
Loans Schedule Of Long-term Debt Instruments 22	$ 2,540

Schedule of Short-term Debt (De

Schedule of Short-term Debt (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Loans Schedule Of Short-term Debt 1	4.05%
Loans Schedule Of Short-term Debt 2	$ 139
Loans Schedule Of Short-term Debt 3	6.00%
Loans Schedule Of Short-term Debt 4	7.50%
Loans Schedule Of Short-term Debt 5	$ 166
Loans Schedule Of Short-term Debt 6	6.00%
Loans Schedule Of Short-term Debt 7	$ 54
Loans Schedule Of Short-term Debt 8	5.50%
Loans Schedule Of Short-term Debt 9	$ 35
Loans Schedule Of Short-term Debt 10	5.50%
Loans Schedule Of Short-term Debt 11	$ 43
Loans Schedule Of Short-term Debt 12	2.00%
Loans Schedule Of Short-term Debt 13	$ 529
Loans Schedule Of Short-term Debt 14	$ 966
Loans Schedule Of Short-term Debt 15	7.00%
Loans Schedule Of Short-term Debt 16	$ 1,334
Loans Schedule Of Short-term Debt 17	6.30%
Loans Schedule Of Short-term Debt 18	$ 529
Loans Schedule Of Short-term Debt 19	$ 2,829

Schedule of Fair Value of Ins72

Schedule of Fair Value of Instruments for Financing (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Capital Deficiency Schedule Of Fair Value Of Instruments 1	$ 1,390
Capital Deficiency Schedule Of Fair Value Of Instruments 2	1,529
Capital Deficiency Schedule Of Fair Value Of Instruments 3	1,284
Capital Deficiency Schedule Of Fair Value Of Instruments 4	$ 4,203

Schedule of Fair Value of Priva

Schedule of Fair Value of Private Placements (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Capital Deficiency Schedule Of Warrants 1	$ 192,308
Capital Deficiency Schedule Of Warrants 2	0.40
Capital Deficiency Schedule Of Warrants 3	192,308
Capital Deficiency Schedule Of Warrants 4	7,891,108
Capital Deficiency Schedule Of Warrants 5	0.40
Capital Deficiency Schedule Of Warrants 6	7,891,108
Capital Deficiency Schedule Of Warrants 7	8,083,416
Capital Deficiency Schedule Of Warrants 8	$ 8,083,416

Schedule of Fair Value of Warra

Schedule of Fair Value of Warrants (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Capital Deficiency Schedule Of Fair Value Of Warrants 1	$ 713,023
Capital Deficiency Schedule Of Fair Value Of Warrants 2	0.52
Capital Deficiency Schedule Of Fair Value Of Warrants 3	713,023
Capital Deficiency Schedule Of Fair Value Of Warrants 4	384,615
Capital Deficiency Schedule Of Fair Value Of Warrants 5	0.52
Capital Deficiency Schedule Of Fair Value Of Warrants 6	384,615
Capital Deficiency Schedule Of Fair Value Of Warrants 7	192,308
Capital Deficiency Schedule Of Fair Value Of Warrants 8	0.52
Capital Deficiency Schedule Of Fair Value Of Warrants 9	192,308
Capital Deficiency Schedule Of Fair Value Of Warrants 10	144,230
Capital Deficiency Schedule Of Fair Value Of Warrants 11	0.52
Capital Deficiency Schedule Of Fair Value Of Warrants 12	144,230
Capital Deficiency Schedule Of Fair Value Of Warrants 13	115,385
Capital Deficiency Schedule Of Fair Value Of Warrants 14	0.52
Capital Deficiency Schedule Of Fair Value Of Warrants 15	115,385
Capital Deficiency Schedule Of Fair Value Of Warrants 16	2,358,490
Capital Deficiency Schedule Of Fair Value Of Warrants 17	0.53
Capital Deficiency Schedule Of Fair Value Of Warrants 18	2,358,490
Capital Deficiency Schedule Of Fair Value Of Warrants 19	3,908,051
Capital Deficiency Schedule Of Fair Value Of Warrants 20	$ 3,908,051

Schedule of Earnings Per Share,

Schedule of Earnings Per Share, Basic and Diluted (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 1	$ 4,461
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 2	5,504
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 3	55,798,416
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 4	$ 54,162,596
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 5	0.08
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 6	0.10
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 7	$ 4,461
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 8	5,504
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 9	1,272
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 10	559
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 11	598
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 12	6,292
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 13	6,102
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 14	55,798,416
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 15	54,162,596
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 16	873,380
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 17	249,116
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 18	559,373
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 19	56,920,912
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 20	$ 54,721,969
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 21	0.11
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 22	0.11

Schedule of Share-based Payment

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 1	$ 0.53
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 2	$ 0.53
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 3	0.63
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 4	0.00%
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 5	0.00%
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 6	85.70%
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 7	100.5
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 8	100.60%
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 8	1.68%
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 10	1.67
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 11	2.52%
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 10	2.5
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 11	$ 5
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 12	$ 10

Schedule of Stock Options Grant

Schedule of Stock Options Granted to Employees and Directors (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 1	$ 12,809,455
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 2	0.27
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 3	$ 12,294,765
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 4	0.265
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 5	$ 500,000
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 6	0.53
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 7	$ 2,707,300
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 8	0.194
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 9	$ (623,806)
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 10	0.001
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 11	$ (2,440,120)
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 12	0.68
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 13	$ (528,125)
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 14	0.5
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 15	$ (1,568,804)
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 16	0.205
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 17	$ 10,341,210
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 18	0.16
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 19	$ 12,809,455
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 20	0.27
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 21	$ 8,696,162
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 22	0.09
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 23	$ 9,661,548
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 24	0.568

Schedule of Information Stock O

Schedule of Information Stock Options Granted to Employees and Directors (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 1	0.0001
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 2	$ 4,439,205
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 3	7.1
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 4	0.0001
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 5	$ 1,464
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 6	0.001
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 7	$ 3,338,285
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 8	6.2
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 9	0.001
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 10	$ 1,098
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 11	0.50
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 12	$ 400,000
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 13	8.7
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 14	0.5
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 15	0.53
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 16	$ 500,000
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 17	9.5
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 18	0.53
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 19	0.75
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 20	$ 250,000
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 21	7.6
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 22	0.75
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 23	0.79
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 24	$ 942,520
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 25	6.6
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 26	0.79
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 27	0.85
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 28	$ 471,200
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 29	6.5
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 30	0.85
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 31	0.17
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 32	$ 10,341,210
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 33	6.9
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 34	1.016
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 35	$ 2,562

Schedule of Disclosure of Share

Schedule of Disclosure of Share-based Compensation Stock Options Exercisable (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 1	0.0001
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 2	$ 3,584,645
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 3	0.3
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 4	0.001
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 5	$ 3,338,285
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 6	$ 3
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 7	0.50
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 8	$ 325,000
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 9	$ 163
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 10	0.53
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 11	$ 500,000
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 12	$ 265
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 13	0.75
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 14	$ 100,000
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 15	$ 75
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 16	0.79
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 17	$ 565,512
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 18	$ 447
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 19	0.85
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 20	$ 282,720
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 21	240
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 22	8,696,162
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 23	$ 1,193

Schedule of Fair Value of Stock

Schedule of Fair Value of Stock Options Granted Valuation Assumptions (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 1	$ 0.51
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 2	0.00%
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 3	100.00%
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 4	0.11
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 5	0.95%
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 6	$ 1
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 7	$ 3

Schedule of Fair Value of Sto81

Schedule of Fair Value of Stock Options Granted Valuation Assumptions By Using Hybrid Model[Table Text Block] (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 1	$ 0.65
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 2	0.53
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 3	$ 0.53
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 4	0.00%
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 5	0.00%
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 6	86.00%
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 7	89.00%
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 8	101.00%
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 9	1.34%
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 10	1.42%
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 11	1.31%
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 12	$ 5
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 13	$ 4

Schedule of Stock Options Gra82

Schedule of Stock Options Granted to Non-Employees (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 1	$ 2,458,104
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 2	0.75
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 3	$ 1,378,104
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 4	0.95
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 5	$ 200,000
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 6	0.51
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 7	$ 2,080,000
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 8	0.51
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 9	$ (1,000,000)
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 10	0.52
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 11	$ 2,658,104
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 12	0.75
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 13	$ 2,458,104
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 14	0.75
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 15	$ 1,521,624
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 16	0.65
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 17	$ 1,171,384
Stock Based Compensation Schedule Of Share-based Compensation, Stock Options Granted To Consultants 18	0.77

Schedule of Information Options

Schedule of Information Options Granted to Non-Employees (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 1	0.50
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 2	$ 1,080,000
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 3	2.67
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 4	0.50
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 5	0.52
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 6	$ 100,000
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 7	4.55
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 8	0.52
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 9	0.61
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 10	$ 100,000
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 11	6.98
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 12	0.61
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 13	0.65
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 14	$ 100,000
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 15	4.2
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 16	0.65
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 17	0.69
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 18	$ 706,904
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 19	6.17
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 20	0.69
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 21	0.96
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 22	$ 100,000
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 23	7.35
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 24	0.96
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 25	1.40
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 26	$ 471,200
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 27	6.38
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 28	1.40
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 29	$ 2,658,104
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 30	4.72
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 31	0.75
Stock Based Compensation Schedule Of Share-based Compensation Arrangement By Share-based Payment Award, Options Granted To Employees Outstanding 32	$ 0

Schedule of Stock Options Exerc

Schedule of Stock Options Exercisable (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Stock Based Compensation Schedule Of Stock Options Exercisable 1	0.50
Stock Based Compensation Schedule Of Stock Options Exercisable 2	$ 432,000
Stock Based Compensation Schedule Of Stock Options Exercisable 3	$ 216
Stock Based Compensation Schedule Of Stock Options Exercisable 4	0.61
Stock Based Compensation Schedule Of Stock Options Exercisable 5	$ 60,000
Stock Based Compensation Schedule Of Stock Options Exercisable 6	$ 37
Stock Based Compensation Schedule Of Stock Options Exercisable 7	0.69
Stock Based Compensation Schedule Of Stock Options Exercisable 8	$ 706,904
Stock Based Compensation Schedule Of Stock Options Exercisable 9	$ 488
Stock Based Compensation Schedule Of Stock Options Exercisable 10	0.96
Stock Based Compensation Schedule Of Stock Options Exercisable 11	$ 40,000
Stock Based Compensation Schedule Of Stock Options Exercisable 12	$ 38
Stock Based Compensation Schedule Of Stock Options Exercisable 13	1.40
Stock Based Compensation Schedule Of Stock Options Exercisable 14	$ 282,720
Stock Based Compensation Schedule Of Stock Options Exercisable 15	396
Stock Based Compensation Schedule Of Stock Options Exercisable 16	1,521,624
Stock Based Compensation Schedule Of Stock Options Exercisable 17	$ 1,175

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Taxes Schedule Of Deferred Tax Assets 1	$ 5,658
Taxes Schedule Of Deferred Tax Assets 2	1,626
Taxes Schedule Of Deferred Tax Assets 3	(178)
Taxes Schedule Of Deferred Tax Assets 4	230
Taxes Schedule Of Deferred Tax Assets 5	31
Taxes Schedule Of Deferred Tax Assets 6	14
Taxes Schedule Of Deferred Tax Assets 7	268
Taxes Schedule Of Deferred Tax Assets 8	45
Taxes Schedule Of Deferred Tax Assets 9	(508)
Taxes Schedule Of Deferred Tax Assets 10	(5,661)
Taxes Schedule Of Deferred Tax Assets 11	(2,982)
Taxes Schedule Of Deferred Tax Assets 12	(1,870)
Taxes Schedule Of Deferred Tax Assets 13	(3,327)
Taxes Schedule Of Deferred Tax Assets 14	$ 0

Schedule of Valuation Allowance

Schedule of Valuation Allowance, Activity (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Taxes Schedule Of Valuation Allowance, Activity 1	$ (1,870)
Taxes Schedule Of Valuation Allowance, Activity 2	(1,212)
Taxes Schedule Of Valuation Allowance, Activity 3	(1,112)
Taxes Schedule Of Valuation Allowance, Activity 4	(658)
Taxes Schedule Of Valuation Allowance, Activity 5	(2,982)
Taxes Schedule Of Valuation Allowance, Activity 6	$ (1,870)

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities at Fair Value (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 1	$ 1,382
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 2	560
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 3	1,533
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 4	289
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 5	992
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 6	$ 1,888

Schedule of Fair Value, Assumpt

Schedule of Fair Value, Assumptions Used (Details)	12 Months Ended
	Nov. 30, 2015USD ($)	Nov. 30, 2014USD ($)
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 1	0.33
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 2	0.33
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 3	0.33
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 4	87.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 5	98.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 6	87.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 7	88.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 8	14.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 9	$ 0
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 10	18.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 11	0.44%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 12	1.24%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 13	0.42%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 14	2.9
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 15	$ 3
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 16	0.08
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 17	0.87
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 18	0.8
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 19	0.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 20	0.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 21	0.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 1		$ 0.65
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 2		$ 0.65
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 3		0.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 4		0.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 5		100.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 6		100.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 7		0.03
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 8		0.11%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 9		0.04%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 10		0.3
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 11		0.8
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 12		0.08

Schedule of Sensitivity Analysi

Schedule of Sensitivity Analysis of Fair Value, Warrants (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Warrants 1	$ 1,263
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Warrants 2	1,382
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Warrants 3	$ 1,486

Schedule of Sensitivity Analy90

Schedule of Sensitivity Analysis of Changes in Fair Value, Derivatives (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Derivatives 1	$ 1,502
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Derivatives 2	1,533
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Derivatives 3	$ 1,552

Schedule of Sensitivity Analy91

Schedule of Sensitivity Analysis of Changes in Fair Value, Convertible Bonds (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Convertible Bonds 1	$ 1,885
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Convertible Bonds 2	1,888
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Convertible Bonds 3	$ 1,920

Schedule of Fair Value of Finan

Schedule of Fair Value of Financial Liabilities, Activity (Details) - USD ($)	12 Months Ended
	Nov. 30, 2015	Nov. 30, 2014
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 1	$ 560
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 2	992
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 3	0
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 4	0
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 5	1,390
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 6	112
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 7	3,234
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 8	1,526
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 9	(525)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 10	0
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 11	7
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 12	(43)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 13	(815)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 14	(1,221)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 15	0
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 16	0
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 17	(125)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 18	1,382
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 19	289
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 20	1,888
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 21	$ 1,533
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 1		$ 1,158
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 2		574
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 3		(348)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 4		418
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 5		(250)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 6		560
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 7		$ 992

Schedule of Research and Develo

Schedule of Research and Development Expenses (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Research And Development Expenses, Net Schedule Of Research And Development Expenses 1	$ 1,860
Research And Development Expenses, Net Schedule Of Research And Development Expenses 2	2,478
Research And Development Expenses, Net Schedule Of Research And Development Expenses 3	(793)
Research And Development Expenses, Net Schedule Of Research And Development Expenses 4	(929)
Research And Development Expenses, Net Schedule Of Research And Development Expenses 5	1,067
Research And Development Expenses, Net Schedule Of Research And Development Expenses 6	$ 1,549

Schedule of Financial Expenses

Schedule of Financial Expenses (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Financial Expenses (incomes), Net Schedule Of Financial Expenses 1	$ (2,596)
Financial Expenses (incomes), Net Schedule Of Financial Expenses 2	(180)
Financial Expenses (incomes), Net Schedule Of Financial Expenses 3	726
Financial Expenses (incomes), Net Schedule Of Financial Expenses 4	691
Financial Expenses (incomes), Net Schedule Of Financial Expenses 5	135
Financial Expenses (incomes), Net Schedule Of Financial Expenses 6	50
Financial Expenses (incomes), Net Schedule Of Financial Expenses 7	10
Financial Expenses (incomes), Net Schedule Of Financial Expenses 8	260
Financial Expenses (incomes), Net Schedule Of Financial Expenses 9	(30)
Financial Expenses (incomes), Net Schedule Of Financial Expenses 10	11
Financial Expenses (incomes), Net Schedule Of Financial Expenses 11	(1,850)
Financial Expenses (incomes), Net Schedule Of Financial Expenses 12	$ 927

Schedule of Related Party Trans

Schedule of Related Party Transactions (Details)	12 Months Ended
	Nov. 30, 2015USD ($)
Related Party Transactions Schedule Of Related Party Transactions 1	$ 57
Related Party Transactions Schedule Of Related Party Transactions 2	34
Related Party Transactions Schedule Of Related Party Transactions 3	71
Related Party Transactions Schedule Of Related Party Transactions 4	39
Related Party Transactions Schedule Of Related Party Transactions 5	$ 350